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ABSTRACT  
 
In South Africa, breast cancer dominates other forms of cancer affecting women in 
both prevalence and mortality rates according to the National Cancer Registry. The 
incidence and cost of breast cancer have been on the rise particularly in developing 
countries. To date, there has been no study on the financial burden of breast cancer in 
the South African public sector. The aim of this study was to develop a method of 
costing breast cancer treatment with chemotherapy at Groote Schuur hospital (GSH), 
a government hospital. The objective was to determine the direct medical costs 
associated with breast cancer treatment and management of chemotherapy adverse 
events. 
 
Retrospective patient level data were collected from electronic databases and patient 
folders between 2013 and 2015. Electronic data were obtained for all patients treated 
with chemotherapy. Two hundred (200) patients‟ folders were randomly selected to 
supplement data from the electronic databases. The main sources of cost were the 
Uniform Patient Fee Schedule (UPFS) and time and motion studies. Cost analyses 
were conducted at patient level from the health funder‟s perspective. Multiple 
regression analysis was used to investigate the relationship between the dependent 
variable (cost of treatment) and a set of independent variables (clinical stage, age at 
diagnosis, status of treatment, protocol and treatment approach) of the study sample.  
 
The total direct medical cost for treatment of breast cancer at GSH for 200 patients 
was R3 154 877.90 and the average episode of care cost was R15 774.39 per patient. 
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The cost of management of adverse events arising from the various treatment 
modalities was on average R13 133 per patient. It was found that the cost of treating a 
patient with adverse events is 1.8 times more than the cost of treating a patient 
without adverse events. Of the patients, 86.5% managed to complete their prescribed 
chemotherapy and the average cost of treatment of these patients was 1.3 times more 
than the average for patients who could not complete their treatment. The cost of 
compounding of chemotherapy by the pharmacist, determined by time and motion 
studies, increased the total cost of chemotherapy medicines by 5.3%. It was found in 
this study that the cost of compounding of chemotherapy medicines was not 
accounted for by the UPFS. 
 
A decision tree was developed to estimate the cost of treatment of breast cancer 
based on the probabilities of the stage of breast cancer and whether the treatment 
was completed or not. The model utilised a formula of calculating the total episode of 
care costs using costs obtained from the study and respective probabilities.  
 
In conclusion, the method of costing of breast cancer was developed with 2 scenarios 
of costing, i.e. scenario 1 (costs derived from UPFS) and scenario 2 (costs derived 
from the UPFS and the time and motion studies). The cost of treatment and its 
adverse events was determined at patient level according to the GSH treatment 
protocol. The method, scenarios and predictive model developed in this study are 
crucial for calculating episode of care costs and can be used by the funder of care 
(government) for improved budget development.  
http://etd.uwc.ac.za
vi 
 
DECLARATION 
 
I, NYASHA GUZHA declare that the entirety of the work contained in this thesis, 
Development of a model to predict the cost of treatment of breast cancer with 
chemotherapy at Groote Schuur hospital, is my own original work, that it has not been 
submitted before for any degree or examination in any other university, and that all the 
sources I have used or quoted have been indicated and acknowledged as complete 
references  
 
 
November 2017 
 
 
Signed:  
 
 
 
 
 
 
http://etd.uwc.ac.za
vii 
 
ACKNOWLEDGEMENTS 
Prima facea, I am grateful to God Almighty for His grace, wisdom and good health 
that were necessary to complete this venture. 
I place on record, Professor Praneet Valodia, my supervisor, School of Pharmacy, 
UWC. I am extremely thankful and indebted to him for sharing his expertise, valuable 
guidance, encouragement and unparalleled patience to me during the course of this 
project. Thank you for challenging me to be a better person. 
I am also grateful to my co-supervisor, Professor Nadine Butler, School of 
Pharmacy, UWC, for her continuous encouragement and support throughout the 
duration of my studies. I am gratefully indebted to her for her very valuable comments 
on the thesis.  
I wish to express my sincere thanks to the following for their contributions during the 
course of the study:  
Professor Raymond Abratt, former Director of the Radiation Oncology department, 
GSH, for granting approval to use the department as my research site. 
Doctor Leon van Wijk, my liaison person at GSH, for his wealth of advice and 
enormous heart that is willing to help in every way he can and to the rest of the team 
of doctors, nurses and clerical staff at Radiation Oncology department, GSH who 
made sure the process of data collection flowed effortlessly.  
Ms Wendy Bryant and Ms Salwa Kriel, Medical Informatics department, GSH, for 
their assistance with extracting data from the hospital database.  
http://etd.uwc.ac.za
viii 
 
Mr Kobus Botha, developer of the EPR database, for his input during data collection.  
Ms Vanishree Naicker, Pharmacy manager and Theresa Blockman, Director of 
Information Management, Tygerberg Hospital, for their assistance and insight towards 
chemotherapy medicine prices and fees.  
Ms Karin Maritz, UPFS Patient Fees: Compliance Auditing, Training & Support, for 
her assistance with UPFS pricing.  
Ms Suzette Munroe, GSH case manager, for her valued input towards hospital billing 
system and fees. 
Mr Lourens Wepener, for his time and assistance with the cost template.  
Mr Daniel Adeniyi, School of Postgraduate Studies, UWC, for his input with regards 
to data analysis and statistics.  
To my family, I must express my profound gratitude to my parents for planting within 
me a seed of passion for greater things. Thank you for supporting me and giving me a 
vision in life. I am forever indebted to my husband Doctor Makomborero Nyoni for 
providing me with unfailing emotional support and continuous encouragement 
throughout the process of researching and writing of this thesis.  
Finally to my son, Prince Grey Nyoni, your arrival during the course of this study was 
my motivation to continue working hard and see this project complete. Thank you for 
being a good boy during the study period.  
This accomplishment would not have been possible without the aforementioned. 
Thank you. 
http://etd.uwc.ac.za
ix 
 
 
 
 
 
 
 
 
 
 
Galatians 6:9, 
And let us not grow weary in doing well,  
for in due season we shall reap, if we do not give up! 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za
x 
 
TABLE OF CONTENTS  
Title page 
Keywords           i 
Glossary of abbreviations         ii 
Abstract           iv 
Declaration           vi 
Acknowledgements          vii 
Table of contents          x 
List of tables           xvi 
List of figures          xviii 
List of annexures          xix 
 
  
Chapter 1 INTRODUCTION                    1 
   
Chapter 2 LITERATURE REVIEW           4 
 2.1  Global incidence and prevalence of breast cancer       5 
2.2  Incidence and prevalence of breast cancer in South Africa         6 
2.3  Breast cancer           7 
2.4  Treatment of breast cancer         7 
2.4.1  Chemotherapy in breast cancer treatment        8 
2.5  Cost of breast cancer treatment           9 
2.5.1  Cost drivers and factors affecting cost of breast cancer              13 
2.5.2  Adverse events of chemotherapy use        14 
2.5.3  Selection of cost components          16 
http://etd.uwc.ac.za
xi 
 
2.5.4  Methods used in cancer costing         17 
2.5.5  Data sources used            19 
2.6  Time and motion in costing studies        20 
2.7  Overall comment on literature review                                          21
  
Chapter 3 MAP OF WORK 
 3.1  Study aim and objectives          22 
3.1.1  Aim             22 
3.1.2  Objectives            22 
3.2  Study flow summary                   23 
3.3  Predictive model development                  26
  
Chapter 4 METHODS  
4.1  Selection of study site          27 
4.2  Patient selection                    28 
4.2.1  Inclusion criteria          28 
4.2.2  Exclusion criteria                    28 
4.3  Study design           29 
4.4  Extraction timeline          29 
4.5  Patient extraction          30 
4.5.1  Electronic database extraction        30 
4.5.2  Sampling           31 
4.6  Data collection          31 
4.6.1  Electronic database          31 
4.6.1.1 Data extracted from electronic database of patient records        32 
4.6.2  Folder data collection         34 
http://etd.uwc.ac.za
xii 
 
4.6.2.1 Data extracted from the patient folders       34 
4.7  Validation           36 
4.7.1  Diagnosis validation                    36 
4.7.2  Chemotherapy dose calculation        36 
4.8  Sources of cost          37 
4.8.1  Time and motion studies         38 
4.8.1.1 Chemotherapy compounding time       39 
4.8.1.2 Chemotherapy administration time                 40 
4.8.1.3 Doctor consultation time         40 
4.9  Cost components studied         41 
4.9.1  Chemotherapy medicines         41 
4.9.2  Support medicines          44 
4.9.3  Chemotherapy administration        45 
4.9.4  Outpatient consultations visits                   46 
4.9.4.1 Scheduled visits          46 
4.9.4.2 Emergency visits          46 
4.9.5  Laboratory tests          47 
4.9.6  Scans and imaging          47 
4.9.7  Inpatient hospitalisation                   48 
4.9.8  Adverse events                     48 
4.10  Cost categorisation          50 
4.11  Cost template          51 
4.12  Cost calculation          52 
4.13  Cost analysis           54 
4.13.1  Cost at patient level           54 
http://etd.uwc.ac.za
xiii 
 
4.13.2  Cost per episode of care          54 
4.13.3  Average cost            54 
4.14   Predictive model developed                  55 
4.14.1  Model assumptions           55 
4.15  Statistical analyses           56 
4.16  Ethics             57 
 
Chapter 5  RESULTS 
5.1  Demographics           58 
5.2  Patient clinical characteristics         60 
5.3  Cost components           65 
5.3.1   Cost of chemotherapy          65 
5.3.2  Cost of chemotherapy regimens as per GSH protocol      69 
5.3.3  Cost of support medicines          73 
5.3.4  Cost of laboratory tests          74 
5.3.5  Cost of scans and imaging          75 
5.4  Developed cost method: Cost calculation       78 
5.4.1  Cost of components           79 
5.4.2  Cost of breast cancer per episode of care       80 
5.4.3  Cost of management of breast cancer        81 
5.4.4  Total cost of breast cancer          82 
5.5  Cost categorisation           85 
5.5.1  Cost of breast cancer based on clinical stage       86 
5.5.2  Cost of breast cancer based on age at diagnosis      88 
5.5.3  Cost of breast cancer based on treatment approach      89 
http://etd.uwc.ac.za
xiv 
 
5.5.4   Cost of breast cancer based on primary and salvage therapy     90 
5.6  Combined categorisation of costs         90 
5.6.1  Treatment approach versus stage of breast cancer      90 
5.6.2   Episode of care cost versus treatment approach      91 
5.6.3  Episode of care cost versus chemotherapy regimen      92 
5.7  Cost of adverse events          94 
5.8 Model for predicting the cost of treatment:                           
Decision tree model               98 
5.9  Regression model analysis       102 
 
Chapter 6 DISCUSSION          105 
6.1  Demographics and clinical characteristics     106 
6.2  Developed method         107 
6.2.1  Time and motion study        109 
6.2.2  Scenario analysis         111 
6.3  Cost of breast cancer treatment and adverse events    113 
6.3.1  Episode of care cost        113 
6.3.2  Cost drivers and cost of components               115 
6.3.3  Cost of adverse events                 116 
6.3.4  Categorisation of costs        118 
6.4  Predictive model developed       120 
6.5  Limitations of the study        122  
 
 
 
http://etd.uwc.ac.za
xv 
 
Chapter 7 CONCLUSIONS AND RECOMMENDATIONS 
7.1  Conclusions          123 
7.2  Recommendations         125 
 
REFERENCES            127 
 
ANNEXURES            
Annexure 1:  Data collection form         138 
Annexure 2:   Time and motion study: Compounding fee     142 
Annexure 3:  Time and motion study: Administration of chemotherapy   143 
Annexure 4:  Time and motion study: Doctor consultation     143 
Annexure 5:   List of data fields for data collection       144 
Annexure 6:  Ethics approval certificates        145 
Annexure 7:   Statistical analysis         148 
   
   
   
   
   
   
   
   
   
   
 
http://etd.uwc.ac.za
xvi 
 
LIST OF TABLES 
Table 1:  Percentage of patients treated with chemotherapy                  
experiencing adverse events          15 
Table 2:  Breast cancer chemotherapy regimens at GSH        43 
Table 3:  Support medicines classes for patients with breast cancer      44 
Table 4:  The summary for calculation of costs per patient       53 
Table 5:  Clinical characteristics of study population                 61 
Table 6:  Results of the hormone receptor tests                         63 
Table 7:  Prognosis indicator statistics at GSH         65 
Table 8:  Cost per cycle of chemotherapy regimens at GSH       65 
Table 9: Chemotherapy components for the treatment of breast cancer                
at GSH (n=200)            68 
Table 10: Summary of other cost components studied for the treatment                 
of breast cancer at GSH for 200 patients         68 
Table 11: Chemotherapy regimens as utilised by study population       72 
Table 12:  The commonly prescribed medicines and their prices derived            
from the Medical Informatics (MI) and the Tender Price List (TPL)        73 
Table 13:  Cost of laboratory tests (routine and adverse events)                 74 
Table 14:  Laboratory tests conducted for breast cancer patients at GSH     75 
Table 15:  Cost of scans and imaging procedures (routine and adverse events)   76 
Table 16:  Scans and imaging procedures conducted at GSH       76 
Table 17:  UPFS facility fees           77 
http://etd.uwc.ac.za
xvii 
 
Table 18:    The proportion of total costs by complete and incomplete           
chemotherapy treatment           81 
Table 19:  Average cost of management of breast cancer per patient at GSH       82 
Table 20:  Total cost of scenario 1 versus scenario 2 for the treatment of                     
breast cancer            84 
Table 21:  Time and motion study results            85 
Table 22: Cost of treatment per stage of breast cancer for all patients      86 
Table 23:  Cost of treatment per age group          89 
Table 24: Cost of treatment per treatment approach        89 
Table 25:  Cost of treatment per primary and salvage therapy       90 
Table 26:  Treatment approach versus stage of breast cancer        91 
Table 27:  Episode of care cost versus chemotherapy regimen        93 
Table 28:  Occurrences and grade of adverse events           95 
Table 29: Cost of each adverse effect and its component costs (per patient)      96 
Table 30:  Cost of adverse events according to age and stage of cancer at 
diagnosis                                  97 
Table 31:  Probability of patient being diagnosed with breast cancer            
according to status of treatment and stage of breast cancer      98 
Table 32: Estimated cost of treating breast cancer patients                         100 
Table 33:  Model summary for total cost of treatment of breast cancer   103 
 
 
http://etd.uwc.ac.za
xviii 
 
LIST OF FIGURES 
Figure 1:  Summary flow diagram of study          25 
Figure 2: Patient selection            59 
Figure 3:  Component costs for chemotherapy as they appear in the                         
model scenario 1 (n=200)                       67 
Figure 4:  Component costs for chemotherapy as they appear in the model               
scenario 2 (n=200)             67 
Figure 5: Number of patients who received chemotherapy regimens      70 
Figure 6:  Average cost per patient of each regimen used at GSH       71 
Figure 7: The cost components of breast cancer treatment (n=200)      80 
Figure 8:  The Wilk‟s Lambda test for statistical significance differences                 
of cost between the stages of breast cancer                 88 
Figure 9: The episode of care cost against treatment approach      92 
Figure 10: Decision tree analysis diagram with costs      101 
 
 
 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za
xix 
 
LIST OF ANNEXURES 
Annexure 1:  Data collection form         138 
Annexure 2:   Time and motion study: Compounding fee     142 
Annexure 3:  Time and motion study: Administration of chemotherapy   143 
Annexure 4:  Time and motion study: Doctor consultation     143 
Annexure 5:   List of data fields for data collection       144 
Annexure 6:  Ethics approval certificates        145 
Annexure 7:   Statistical analysis         148 
     
 
 
 
 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za
1 
 
CHAPTER 1 
INTRODUCTION 
Cancer has proved to be one of the major health care challenges that funders of care 
should vigorously assess to reduce the economic burden imposed. Breast cancer in 
particular has more than 1.7 million women worldwide diagnosed every year 
(Ginsburg et al., 2017). The National Cancer Registry data, published in 2012, 
reported that breast cancer cases comprise of 21.79% of all cancers affecting women 
in South Africa, thus making breast cancer the most prevalent cancer affecting women 
in South Africa (Davari et al., 2013).  
The majority of the burden is dominant in developing countries where there are great 
economic crises and health problems, i.e. delayed diagnosis and lack of funds that 
allow for appropriate treatment (Boutayeb et al., 2010). Breast cancer in South Africa 
is the leading cause of cancer related deaths in women. Projections for future 
mortality rates highlight that the burden of cancer will increase year by year (WHO, 
2010). Apart from the burden on mortality, breast cancer poses a great economic 
burden worldwide. Breast cancer expenditure in South African public sector has not 
been researched and presents a huge gap for budget development and resource 
allocation. Non-peer reviewed literature by Laganparsad (2016), described cancer 
cost as a debt sentence due to the high treatment cost of the disease in the private 
sector. As more than 86% of the population is serviced at public sector hospitals in 
South Africa, it is important to understand the cost of treatment from that perspective.  
The economic evaluation is central to health care decision makers as this will allow 
the proper allocation of budgets for the treatment of breast cancer.  
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The South African health care system is preparing for the introduction of the National 
Health Insurance (NHI). Therefore, it is important that costs of common diseases 
affecting women, such as breast cancer, are known. The knowledge of these costs 
will help the funder of care, i.e. the government in financial planning and allocation of 
already scarce resources. 
 
It is acknowledged that the costs of management of breast cancer and associated 
adverse events are important. Of equal importance is the actual method used to 
calculate the costs, as this can be used on another data set of another hospital. It is 
crucial to develop a method of costing because such a method of costing, according 
to our knowledge, is not available in the public sector in South Africa.  
 
This study was conducted at Groote Schuur hospital (GSH), a tertiary public sector 
hospital. The study was conducted from the perspective of the funder of care. The aim 
of the study was to develop a method and model to predict the cost of breast cancer 
treatment with chemotherapy.  
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The study objectives were to: 
i. develop a method to determine the episode of care cost for breast cancer 
patients treated with chemotherapy at GSH by quantifying the direct medical 
costs and resource use relating to chemotherapy in the management of breast 
cancer; 
ii. determine all the cost components involved in treatment of breast cancer and 
identify the cost drivers; 
iii. develop and compare various scenarios of costing derived from the method of 
costing; 
iv. quantify the cost components crucial for the management of adverse events 
due to chemotherapy; 
v. explore the relationship of the costs between the various types of 
chemotherapy treatment, and to categorise the costs according to stage of 
cancer, age at diagnosis, treatment approach, primary and salvage treatment; 
vi. ascertain the time spent by medical personnel such as nurses and doctors in 
relation to contact with the patient, chemotherapy administration and time spent 
by the pharmacist in preparing or compounding chemotherapy medicines 
through time and motion studies and how these contribute to the total cost of 
treatment; and 
vii. develop a model which could predict the cost of breast cancer care at GSH. 
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CHAPTER 2 
LITERATURE REVIEW 
 
This literature review will focus on the methods used to determine the cost of 
treatment of breast cancer. Where literature is available, the costs associated with 
chemotherapy and its adverse events will also be reviewed. The few available studies 
conducted in this field will be described and evaluated for their relevance to the South 
African public sector.  
 
This literature review was conducted through journal database searches of Pubmed, 
Medline, EbscoHost, Google Scholar and Science Direct, in combination with 
published text-books on the topic. The search strategy employed key words such as 
„cost of chemotherapy‟, „treatment of breast cancer‟, „costing models‟ and „costing 
methodology‟.  
 
The first part of the review highlights the aetiology of breast cancer and an overview of 
prevalence of breast cancer globally and locally. This section is followed by an 
overview of background information on breast cancer more importantly in relation to its 
treatment with chemotherapy and cost of treatment. Finally, an evaluation of the 
different methodologies of costing studies is drawn with the intention of developing an 
appropriate method.  
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2.1 Global incidence and prevalence of breast cancer 
 
Every year, more than 1.7 million women worldwide are diagnosed with breast cancer 
(Ginsburg et al., 2017). Breast cancer is the most prevalent cancer in women globally 
and accounts for approximately 400 000 deaths for each year in the past few years 
(Hoang Lan et al., 2013). An estimated 231 840 new cases of invasive breast cancer 
and 40 290 deaths were expected to occur in the United States of America (USA) 
alone in 2015 (Blumen et al., 2016; De Santis et al., 2015). In the year 2008, an 
estimate of 23% (1.38 million) total global cancer cases and 14% (458,400) of the total 
cancer deaths were due to breast cancer (Davari et al., 2013). The average lifetime 
risk for developing breast cancer was estimated to be 1 in 8 in the USA, citing the 
burden of the disease in a developed country (Langhorne et al., 2007). The mortality 
of breast cancer has been found to be dominant in low and middle-income countries 
(Ginsburg et al., 2017). The reason for the aforementioned is due to limited availability 
of health care resources and good quality facilities for diagnosis and treatment 
services. The study published by Ginsburg and colleagues in 2017, collected data 
from population-based cancer registries obtained from countries of varied 
socioeconomic environments. The study predicted that the number of women with 
breast cancer globally will increase to almost 3.2 million per year by the year 2030 
(Ginsburg et al., 2017).  
 
Another cancer parameter depicting the threat of breast cancer globally is the burden 
of mortality due to breast cancer which varies between developing and developed 
nations. The larger proportion of deaths were recorded in the developing nations 
http://etd.uwc.ac.za
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(Davari et al., 2013; Kruger and Apffelstaedt 2007). However, a steady decline in 
burden of mortality is evident in developed nations, and this has been as a result of 
early detection programmes (Ferlay et al., 2010). The incidence and mortality rates in 
the developing countries such as South Africa are still on the rise by approximately 
5% per year (Groot et al., 2006).  
 
2.2  Incidence and prevalence of breast cancer in South Africa 
The lifetime risk for developing breast cancer is approximately 1 in 26 for South 
African women. According to the data published by CANSA (2012) for the National 
Cancer Registry (NCR), breast cancer cases account for 21.79% of all cancers 
affecting women in South Africa. It is also reported that breast cancer is causing the 
highest mortality among the female cancer patients in South Africa (Dickens et al., 
2014).  
The reported statistics of breast cancer in South Africa show that by province Gauteng 
has the highest prevalence of 40%, followed by the Western Cape with a prevalence 
of 25%, KwaZulu-Natal and the Free State together totaling a prevalence of 30%. The 
remaining prevalence of 5% occurred in the rest of the provinces in South Africa 
(Bateman. 2008). In future, the cancer incidence is projected to increase by 78% by 
2030 in South Africa (Stefan et al., 2013).  
The rise is attributable to multiple factors such as fast paced lifestyles, increasing 
levels of pollution, ageing, obesity and viral infections endemic in the population such 
as HBV/HIV/HPV (Gopal et al., 2014; Stewart. 2014).  
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7 
 
A study by Ginsburg et al. (2017) suggested development of high quality cancer 
registries to capture the trends in incidence, mortality and survival of patients, 
especially in South Africa.  
2.3  Breast cancer 
 
Breast cancer presents as different types and in different stages depending on the 
extent of its spread. A malignancy confined to the ducts or lobules is classified as 
noninvasive and once the cancer cells penetrate the tissue outside the ducts it is 
classified as invasive (Sharma et al., 2010). Invasive ductal carcinoma is the most 
common type of breast cancer, accounting for 80% of breast cancer diagnoses whilst 
more than 15% of the carcinoma diagnosed in the USA is carcinoma in situ (Siegel et 
al., 2015) 
The concerns of the patient with breast cancer range from the timely diagnosis 
procedures, the treatment options, prognosis, costs of medical treatment and 
emotional support. In addition, the overall costs of breast cancer may overwhelm both 
the funder of care and the patient (Hoang Lan et al., 2013).  
2.4 Treatment of breast cancer 
Breast cancer treatment options vary depending on disease characteristics (i.e. 
clinical stage, histologic grade, HER2 status, number of positive lymph nodes, 
hormone receptor status of the tumour) and on patient characteristics (i.e. age and 
menopausal status) (Pallis et al., 2010). The types differ in their response to systemic 
treatment (Weigelt et al., 2010).   
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The management of breast cancer is broadly categorised into surgery, radiotherapy, 
hormonal therapy and chemotherapy.  
2.4.1 Chemotherapy in breast cancer treatment 
 
Research has shown that breast cancer is a systemic disease (Redig and McAllister. 
2013). This supports the use of chemotherapy and hormonal manipulation together 
with surgery and radiotherapy to improve patient survival. Breast cancer 
chemotherapy treatment is classified as adjuvant, neo-adjuvant and palliative. The 
goal of adjuvant and neo-adjuvant chemotherapy is generally curative, whereas the 
goal of chemotherapy in the metastatic stage is more palliative (Van Kleffens et al., 
2004). Adjuvant chemotherapy (post-operative) treatment has markedly reduced rates 
of death due to breast cancer (Parkin et al., 2005). There are several chemotherapy 
combinations used in the treatment of cancer, e.g. the National Comprehensive 
Cancer Network (NCCN) guidelines outline the chemotherapy regimens for different 
types of breast cancer.  
The choice of chemotherapy remains individualised yet patients receive optimal drug 
combinations suitable for better performance (Hultman et al., 2012). The process of 
inhibiting cell proliferation affects all rapidly dividing cells, including some normal cells 
such as hair follicles, thereby causing adverse events. Despite the adverse events, 
use of chemotherapy is supported as the destruction of neoplastic cells occurs to a 
greater extent than the destruction of normal cells.  
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The use of chemotherapy is characterised by therapy efficacy and cost expenditure 
particularly cost associated with adverse events and cost of administration (Allies. 
2008).  
2.5 Cost of breast cancer treatment  
 
The treatment of breast cancer has been shown to be costly and a large proportion of 
health care budgets are channelled towards these treatments. The WHO estimated 
the global total cancer expenditure to be US$1.16 trillion in 2014 (Stewart, World 
Cancer Report). Although no comparable cost data are yet available in the South 
African public sector, in their study Dickens and fellow researchers, (2014) mentioned 
that treatment of breast cancer is available at a „small‟ (no figures were indicated) cost 
within the South Africa‟s public health sector (Dickens et al., 2014). The research was 
a case study of over 1 000 women with breast cancer being treated at a public 
hospital in South Africa. There was no insight into the costs of treatment as the study 
only looked at the relationship between stage of breast cancer at diagnosis and the 
distance travelled by the patient to the diagnostic hospital.  
In an article written by Rachelle Blidner (2013), for the Independent online news, she 
mentioned that in South Africa breast cancer treatment could cost between R700 000 
and R1.5 million per patient in the private sector depending on the treatment protocol 
and on what is required for treatment (Blidner. 2013). She argued that with only 8 
public hospitals equipped with oncology services, access to diagnosis and breast 
cancer care was difficult in South Africa.  
http://etd.uwc.ac.za
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Although important, the estimated cost of breast cancer in the private sector does not 
provide any indication of costs in the public sector, as the costs cannot be 
extrapolated due to the different operation, treatment protocols and pricing 
mechanisms viz. SEP versus tender prices.  
According to the Council of Medical Schemes report, (2017), only 17.6% of the 
population had medical scheme coverage in 2016 leaving most of South African 
patients relying on public sector clinics and hospitals.  
The majority of the cancer cost-based studies have been conducted in developed 
countries. One such cost-based study was conducted by Groot and co-workers in  
2006. In this study health effects of breast cancer interventions and costs were 
compared for three epidemiologically different regions, i.e. Asia, Africa and North 
America. The data was compiled from electronic databases in the three regions. Their 
findings revealed a broad statistical variation and different costing methods among 
regions. The costs per patient per episode of care for stage I chemotherapy treatment 
was US$1 829 in Africa, $24 008 in North America, and $1 188 in Asia (Groot et al., 
2006). The specific African region studied was not mentioned and it was also noted 
that the costs were based on estimates and not actual treatment costs. This highlights 
the need for a local study, to investigate trends and costs that are specific to our 
region. As such, the true detailed perspective of cost of breast cancer in South Africa 
has not been researched. The author argued that the African resources (healthcare 
budgets) are better directed towards treatment of early stage disease and developing 
means for less expensive early diagnosis. 
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An Iranian study conducted at a public hospital, measured the direct medical costs of 
breast cancer with chemotherapy. The data were extracted from patients‟ profiles and 
analysed at patient level. The results indicated that the average direct costs per 
patient per month were US$222.17, $224.61, $316.51 and $828.52 for patient in 
stages I to IV respectively (Davari et al., 2013). The results also showed that the cost 
per month of patients in stage IV was much more than the cost of other stages. It was 
concluded that the direct economic cost of breast cancer in Iran is very high.  
A study in the USA conducted a retrospective analysis of claims data for breast cancer 
patients aged between 18 and 64 years (Blumen et al., 2016). The average cost 
allowed for treatment was US$71 909, $97 066, $159 442 and $182 655 for patients 
in Stage I, II, III and IV respectively (Blumen et al., 2016). The results of the study 
concurred with other published literature, that cost was high for patients whose cancer 
was more advanced at diagnosis (Hoang Lan et al., 2013). Treating advanced cancer 
as compared to early stage cancer is associated with significant incremental costs 
particularly when adverse events occur.  
A 2013 cancer population-based descriptive costing study conducted in Canada, 
estimated health care use and costs in the first year of diagnosis for patients with 7 
common cancers. Patients‟ data were collected from an electronic database. For the 
cohort, chemotherapy cost increased 5-fold from CAD$2 286 to $11 834 for all 
patients. The author assumed the drastic changes were as a result of the rise in use 
of adjuvant chemotherapy following studies which demonstrated that such treatment 
improved patient survival (de Oliveira et al., 2013).  
http://etd.uwc.ac.za
12 
 
Overall, De Oliveira et al. (2013) suggested that the increased incidence of breast 
cancer and the use of latest medicines, such as personalised biological treatment and 
technologies, have led to the growth of cancer expenditure. The increase in incidence 
has been affecting both developed and developing countries largely due to changes in 
lifestyle, diet, increase in age and survival (Ferlay et al., 2010). It was found that the 
primary cause for the increase in the cost of cancer was due to an increase in the 
incidence of cancer (Ferlay et al., 2010). Another study predicted a gradual increase 
in the cost of treatment as a result of the increase in the burden of cancer (Blumen et 
al., 2016). 
The cost of cancer treatment can be reduced in several ways. Some authors, (de 
Oliveira et al., 2013) in Canada, found that costs could be minimised by use of gene 
expression profiling and personalised medicines aimed at specific growth factor 
receptors for women with breast cancer. The advancement of this hypothesis in 
developing countries, i.e. South Africa at present, could be a challenge because of 
lack of resources and funds. 
Some studies suggest that raising awareness and employing effective screening 
methods for some cancers including breast cancer could reduce mortality and 
treatment costs for the funder of care (Lansdorp-vogelaar et al., 2009).  
The screening programme aims to identify cases of cancer in the early stage of the 
disease when appropriate treatment is far less costly and can prevent the fatal 
consequence. A study conducted at the University of Cape Town found that a greater 
proportion of women who were admitted with early stage breast cancer reported to 
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have done self-examination (Hoffman et al., 2001). For colorectal cancer a model was 
developed to test the hypothesis that screening would become cost saving despite 
use of latest chemotherapeutic agents for treatment (Lansdorp-vogelaar et al., 2009). 
This same approach could be translated to breast cancer.  
In summary, a review of the various literature indicated that the cost of cancer 
treatment, in particular breast cancer, differs greatly depending on various factors 
such as economic perspective of study and private or public hospital. The cost studies 
recommended measures to reduce or minimise cost of treatment of cancer.  
2.5.1 Cost drivers and factors affecting cost of breast cancer  
The most common cost driver for cancer treatment is hospitalisation costs (de Oliveira 
et al., 2013; Pagano et al., 2012; Pompen et al., 2009). According to Pagano et al., 
(2012), it was reported that hospitalisation constitutes 50-70% of direct medical costs 
of treatment of cancer. The majority of the costs of treatment are incurred during the 
initial phase of care, i.e. diagnosis and staging (Pagano et al., 2012).  
In Iran, research found that surgery cost was the main cost driver for stages I and II, 
whilst medication cost was the mainstay cost of treatment of stages III and IV breast 
cancer (Davari et al., 2013)  
In 2013, de Oliveira et al, concurred with Pagano et al. (2012) that most of the costs 
are incurred during the year of diagnosis. However, they argued that no resource or 
service was singled out as the cost driver as this is not yet fully understood.  
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In general, the care of cancer patients differed with age. It was reported that elderly 
patients were  less likely to receive the same kind of care as the younger patients 
(Evans et al., 1995; Sillman et al., 1989; Chu et al., 1987; Samet et al., 1986). This 
ultimately influenced the cost of treatment based on the age of patient. According to a 
survey done by Hultman et al. (2012), in Canada, most patients (70%) diagnosed with 
breast cancer were younger than 65 years. A few years later in the same country, 
population statistics reported the patients younger than 65 years to be 58.8% of the 
population (Housser et al., 2013). This means that the proportion of breast cancer 
patients is likely to increase when the population below 65 years increases. The costs 
of treatment are dependent on the age of patient (Yabroff et al., 2008). The direct 
costs are also dependent on stage of disease (Korpela et al., 2011) and the 
occurrence of adverse events (Hassett et al., 2006). 
2.5.2 Adverse events of chemotherapy use 
 
Chemotherapy medicines were reported to be the highest cause of serious adverse 
events in women undergoing treatment of breast cancer (Hassett et al., 2006). The 
cost of serious adverse events experienced by women receiving chemotherapy for 
breast cancer is unknown (Paessens et al., 2011). A comparison of occurrence of 
adverse events in women who received chemotherapy and women who did not was 
conducted in the USA (Hassett et al., 2006). It was found that women who received 
chemotherapy were more likely to be hospitalised, i.e. 61% versus 42% of women 
who did not receive chemotherapy.  
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There was a statistical difference indicating that chemotherapy recipients incurred 
substantial incremental costs related to adverse events due to additional therapeutic 
interventions, hospitalisation, ambulatory or emergency encounters. A population 
based study suggests that drug related adverse events contribute immensely towards 
costs of hospitalisation, emergency treatment and mortality (Hassett et al., 2006). The 
table below (Table 1) shows the prevalence of adverse events as they occurred in 2 
studies conducted in 2006 (Hassett et al., 2006; Russo et al., 2006). In both studies, 
fever, infection and neutropenia were most prevalent. Although the studies were 
conducted in different countries, it was evident that the prevalence of adverse events 
generally increased as the study sample increased. 
Table 1: Percentage of patients treated with chemotherapy experiencing 
adverse events 
Author, year Type of 
cancer  
Number of 
patients 
included in 
the study 
Country Adverse events Prevalence 
(%) 
Hassett et al., 
2006 
Breast  4097 USA Fever/ infection 
Neutropenia 
Anaemia 
Constitutional 
symptoms 
Electrolyte 
disorders 
Nausea, diarrhoea 
DVT 
Malnutrition 
8.4 
5.5 
2.2 
 
2.0 
 
2.5 
2.4 
1.2 
0.9 
Russo et al., 
2006 
Breast  847 Italy Fever/ infection 
Neutropenia 
Anaemia 
Constitutional 
symptoms 
Electrolyte 
disorders 
Nausea, diarrhoea 
DVT 
Malnutrition 
5.1 
6.5 
5.6 
 
0.4 
 
0.8 
0.6 
0.2 
1.1 
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2.5.3 Selection of cost components  
 
The literature review indicates that the cost categories for breast cancer treatment 
were selected based on the nature and objective of the study. The major cost 
components used in other studies included medicines, hospital stay, outpatient 
(ambulatory procedure) visits, consultations, laboratory tests and scans (Pettersson et 
al., 2012; Braud et al., 2003). Other components were categorised as a combination 
of individual components, e.g. cost of management of adverse events. 
Depending on the nature and objectives of the study, cost components can be 
excluded or included. Here are some examples from the literature. A study conducted 
by Demeter et al., (2007), excluded community health care events, i.e. visits to 
primary health care clinics, private consultations and home-based palliative care. The 
reason for exclusion was that the study measured cost from the economic perspective 
of the health care institution. The visits to other clinics or home-based palliative care 
did not have an effect on the expenditure of resources of the hospital and therefore 
were excluded. There are other components that were not taken into account by the 
authors Boutayeb et al. (2010), these included the cost of genetic counselling for high 
risk patients, e.g. BRCA gene testing and fertility counselling if the patient was 
premenopausal. 
In another study that measured frequency and cost of chemotherapy related adverse 
events, the cost of outpatients visits was not taken into account (Hassett et al., 2006). 
The study excluded outpatient visits to avoid over sampling bias given that 
chemotherapy patients normally have frequent outpatient visits. Scheduled outpatient 
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visits do not represent cost of adverse events although it is crucial to note that 
emergency outpatient visits for patients on chemotherapy were related to the cost of 
adverse events. A patient undergoes numerous tests and procedures for diagnosis, 
some of the tests were repeated whilst some were not performed on the patient at all.  
When determining the cost of diagnostic tests, Evans et al. (1995), excluded this 
excessive testing in their model as it was difficult to incorporate this variability. To deal 
with excessive testing, specific information from patient folders can be used. 
2.5.4 Methods used in cancer costing 
According to Chien and Shih (2012), the cost of cancer care can be measured in two 
ways; these are the „attributable cost approach‟ and the „net cost approach‟. The 
attributable cost approach measures the cost of cancer related medical services whilst 
the net cost approach compares cost between cancer and non-cancer populations. 
Whilst the former is more favourable, it has associated challenges, i.e. defining cancer 
related medical services. However, it allows flexibility whereby one can choose to 
eliminate certain cost categories, for example surgery or radiotherapy, and focus on 
chemotherapy (Chien and Shih 2012). 
In the study conducted by Haywood et al. in 2012, tasks associated with 
administration of intravenous chemotherapy were identified and cost thereof 
determined from a health care system perspective. A model was developed which 
incorporated the tasks associated with chemotherapy administration, as well as the 
costs of resource use. The nurses‟ and pharmacists‟ time taken to perform their 
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specific roles related to chemotherapy administration were measured and cost 
derived.  
The study conducted by de Oliveira et al. (2013), measured trends in resource use 
and cost for all health care services utilised in the treatment of several cancers. The 
researcher used administrative electronic data captured in various databases for a 12 
month period after diagnosis. They examined the trends of use and mean costs for 
cancer related surgery, chemotherapy, radiotherapy and other cancer related 
admissions to hospital, as well as home care, for a cohort of about 200 000 patients. 
In Paessens et al. (2011), a combination of patient interviews and pre-planned chart 
review was employed for data collection. The study enrolled 373 patients for the 
period of their treatment with chemotherapy. The costs were determined from a 
provider perspective.  
Evans et al. (1995), explained another method of estimating the resource utilisation 
„hotel‟ costs such as heating, security, housekeeping and lighting called the hotel 
approximation method. This method assumes a per diem cost of hospitalisation that is 
equal over all inpatient days regardless of the reason of admission. The Uniform 
Patient Fee Schedule (UPFS) in South Africa employs the same assumption 
equivalent to the hotel approximation method. The UPFS provides a guide for pricing 
of public hospital services and resources given to private fee-paying patients. 
Developing cost models provides a timely consistent and transparent approach to 
estimating treatment costs of standard or alternative therapy (Haywood et al., 2012). 
This information is crucial for local policy makers in estimating cost of treatment. 
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2.5.5 Data sources used 
 
Several studies on the costing of cancer therapy have relied on administration data 
mainly from patient folders as the source of data (Iezzoni., 1997). Data from patient 
folders is reliable and could provide accurate results if doctors or nurses wrote out 
detailed notes. Information written in the folder is patient specific rather than protocol-
based (Pagano et al., 2012) and therefore resource use can be measured at patient 
level. Studies that utilised folder data in their methodology were Davari et al. (2013); 
Hultman et al., (2012); and Demeter et al., (2007). 
Another commonly utilised source of data for costing is the use of hospital computer 
databases or medical scheme registries. The electronic data source was utilised by de 
Oliveira et al. (2013); Haywood et al. (2012); and Petterson et al. (2012). The study 
conducted by Nomane et al. (2012) highlighted the benefits of combining both data 
sources for a study costing the management of diabetes mellitus at Groote Schuur 
hospital (GSH). Developing countries, for example, South Africa are relying on rarely 
updated statistics published by the NCR in 2006, 2010 and latest in 2012. This being 
greatly attributed to data unavailability and lack of current local cancer registries 
(Kruger and Apffelstaedt. 2007). This further emphasises the necessity of the 
development of a national registry.  
The literature sources utilised focused on determining various cancer costs from the 
perspective of the health care funder which is the government. The perspective of the 
funder relies on costs incurred by the hospital and does not include indirect or patient 
extra costs due to cancer such as transportation, home-based care, food or 
accommodation. 
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2.6 Time and motion in costing studies 
 
Observational time and motion studies provide an accurate measure of the time spent 
by health personnel performing individual tasks (Calhoun et al., 2005). 
The time spent by the pharmacist compounding chemotherapy infusions was 
analysed by capturing tasks performed by the pharmacist in a time and motion study 
(Patton. 2011). The tool was used to evaluate the drug-related cost of compounding 
chemotherapy. The tasks involved in the time recording were identified through 
consultation with the specialist and the pharmacist. Thereafter, a flow chart of events 
was developed with the intention of maximising accuracy.  
The National Patient Advocate Foundation (2005), in their study introduced another 
methodology of time and motion study motivated by the beta test which determined a 
potential miss of information if time and motion is based only on top identified drugs 
(Brixner et al., 2005). The survey assessed all tasks conducted by the pharmacist in a 
specified period of time (in one shift). A list of duties a pharmacist is responsible for on 
a typical day of work was developed and if a task not listed was performed, it was 
noted separately. The methodology improved their quality of results. A broader 
analysis is crucial when resources are sufficient.  
Time and motion studies do not only include cost of resource use but an aspect of 
time spent on the task such as nurses‟ time administering IV infusion or pharmacists‟ 
time on compounding and preparing the medicines (Haywood et al., 2012). 
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2.7 Overall comment on literature review 
 
Escalating cancer treatment costs has made it crucial to evaluate the resources 
utilised in managing the treatment of cancer, not only in South Africa, but globally. A 
review of literature revealed that no studies have been published in South Africa on 
the total cost or the episode of care of breast cancer treatment including the adverse 
events of treatment. There was not a single study that portrayed a methodology 
similar to all the objectives set out for our study. The studies analysed helped in 
shaping the design of the current study. These differences in cost studies show that 
there is no standard method for estimating the costs of breast cancer treatment. An 
important consideration when assessing the cost studies is the perspective of the 
study as this can affect the way in which the cost results are interpreted. There are 3 
main perspectives from which these studies were conducted, i.e. (i) the patient, (ii) the 
provider of health care and (iii) the funder of the treatment (Akobundu et al., 2006). 
The focus on this literature review was from the perspective of the funder. 
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CHAPTER 3 
MAP OF WORK 
This section of the thesis is aimed at providing a brief theoretical framework of why 
and how the study was conducted. This study was conducted following a gap that was 
identified in the public sector on the treatment of breast cancer. It was also found that 
there is currently no data that quantified the costs of treatment of breast cancer in 
South Africa in the public hospitals. This study was developed to determine the cost of 
breast cancer treatment, particularly chemotherapy treatment. The full details of the 
method are described in the next chapter.  
3.1 Study aim and objectives 
3.1.1 Aim 
The aim of the study was to develop a method and a model to predict the cost of 
breast cancer treatment with chemotherapy.  
 
3.1.2  Objectives 
The study objectives were to: 
i. develop a method to determine the episode of care cost for breast cancer 
patients treated with chemotherapy at GSH by quantifying the direct medical 
costs and resource use relating to chemotherapy in the management of breast 
cancer; 
ii. determine all the cost components involved in treatment of breast cancer and 
identify the cost drivers; 
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iii. develop and compare various scenarios of costing derived from the method of 
costing; 
iv. quantify the cost components crucial for the management of adverse events 
due to chemotherapy; 
v. explore the relationship of the costs between the various types of 
chemotherapy treatment, and to categorise the costs according to stage of 
cancer, age at diagnosis, treatment approach, primary and salvage treatment; 
vi. ascertain the time spent by medical personnel such as nurses and doctors in 
relation to contact with the patient, chemotherapy administration and time spent 
by the pharmacist in preparing or compounding chemotherapy medicines 
through time and motion studies and how these contribute to the total cost of 
treatment; and 
vii. develop a model which could predict the cost of breast cancer care at GSH. 
 
3.2  Study flow summary 
A flow diagram of how the study was conducted is illustrated in Figure 1. The breast 
cancer patients who received chemotherapy from the Radiation Oncology department 
(ROD) at Groote Schuur hospital (GSH) were selected from the electronic databases 
(Medical Informatics and Electronic Patient Records) for possible inclusion. The 
validation of a breast cancer diagnosis was conducted and applied. A random 
selection process was employed to obtain a sample size of 200 patients. The detailed 
methodology is available in Chapter 4. 
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The patient folders of the selected patients were searched from the hospital‟s medical 
records to supplement information recorded on the electronic database.  
Therefore, the two main sources of data utilised at GSH were (1) electronic patient 
records and (2) patient folders. The patient extraction was conducted in line with the 
study‟s inclusion and exclusion criteria.  
The collected information was classified and categorised into the following cost 
components: chemotherapy medicines, support medicines, administration of 
chemotherapy, laboratory tests, radiology scans and imaging, doctor visits and 
adverse events. The cost components were then used in the development of a cost 
template.  
Time and motion studies were conducted on a set of new patients and data obtained 
were used on the study sample of 200 patients. Where possible some aspects of the 
total costs were substituted with the costs obtained from the time and motion studies. 
The motivation for conducting time and motion studies was reached when one of the 
cost components was deemed to be not fully accounted for by the Uniform Patient 
Fee Schedule (UPFS), e.g. compounding fee for chemotherapy medicines. We 
ensured that substitution of UPFS costs with time and motion costs did not result in 
double counting. The time and motion study presented an alternative cost for the 
following components: 
i. compounding of chemotherapy cost; 
ii. administration of chemotherapy cost; and 
iii. outpatient doctor consultation cost. 
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Figure 1: Summary flow diagram of study 
Breast cancer 
diagnosis 
Negative Positive 
 Registration in ROD 
Inclusion and exclusion 
criteria (Section 4.2) 
200 patients: data collected 
Cost template: Scenario 1 
(Section 4.12) 
Categorisation of 
costs (Section 4.10) 
Decision tree 
analysis (Section 5.8) 
Statistical and 
regression analysis 
(Section 5.9) 
Cost template: Scenario 2 
(Section 4.12) 
Time and motion 
studies             
(Section 4.8.1) 
 
Cost components created 
(Section 4.9) 
 
Sources of cost           
(Section 4.8) 
Sample extracted from 
electronic database  
(Section 4.5) 
Patient folders randomly 
selected                     
(Section  4.6.2) 
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3.3 Predictive model development 
A predictive model for the management of breast cancer patients at GSH was 
developed. The model was based on the decision tree algorithm and according to the 
current treatment procedures. The data obtained from the 200 patients was used in 
the model development. Probabilities of a breast cancer patient completing treatment 
and the likelihood of presenting with either stage I, II, III or IV cancer at diagnosis were 
taken into account. Cost estimates for an episode of care period were obtained for 
each stage of breast cancer. The model assumed that resource use for all 
components was incurred at GSH. Hence, the full episode of care was considered. 
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CHAPTER 4 
METHODS 
The purpose of this chapter is to provide a detailed description of methods used in the 
study. The research methodology consists of the development of a costing method 
and the development of costing scenarios for the management of breast cancer at 
Groote Schuur hospital (GSH). 
4.1   Selection of study site 
Oncology services for breast cancer in the South African public health sector are 
offered at general or tertiary level hospitals (Vorobiof et al., 2001). GSH is a leading 
tertiary referral hospital located in the Cape Metropole, Western Cape. It is a public 
hospital under the management of the Department of Health in South Africa. GSH is a 
teaching hospital equipped with specialist doctors and nurses as well as equipment for 
diagnosis and treatment of patients with cancer. GSH is a government funded hospital 
which supports the study objective of costing treatment from the perspective of the 
funder of care.  
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4.2   Patient selection 
4.2.1 Inclusion criteria 
Patients were included in the study based on the following criteria: 
i. a diagnosis of breast cancer as confirmed in the patients‟ folders; 
ii. registration date at the Radiation Oncology department (ROD) within the period 
1 April 2013 until 31 March 2015; 
iii. evidence of receipt of chemotherapy with two or more health encounters 
related to breast cancer at the ROD. These could be a doctor consultation in 
Ward LE33 or mammogram scan (Vera-Llonch et al., 2011); and 
iv. 18 years and older. 
 
4.2.2 Exclusion criteria 
Patients were excluded from the study based on the following criteria: 
i. male; 
ii. initiated on hormone therapy but not chemotherapy;  
iii. enrolled in a clinical trial; and 
iv. a primary diagnosis of cancer that is not breast cancer. 
 
 
 
 
http://etd.uwc.ac.za
29 
 
4.3  Study design  
The study was a retrospective cohort analysis. The study reviewed a full episode of 
care for treatment with chemotherapy. The episode of care was defined as the care 
provided from 2 months prior to the date of commencing chemotherapy, during 
chemotherapy and 6 months after the date when the last cycle of chemotherapy was 
administered. This period included a diagnosis phase (period of 2 months prior to start 
of chemotherapy), treatment phase and follow-up phase (period of 6 months after 
completion of chemotherapy). The episode of care was on average a period of 10-12 
months per patient.  
 
 
4.4  Extraction timeline 
Data were extracted for breast cancer patients who were registered at the ROD during 
the period 1 April 2013 until 31 March 2015. The two year period was selected 
because it was the most recent period for which breast cancer incidence data were 
available at the time of extraction.  
The financial year of 1 April to 31 March was selected, because the financial calendar 
year of the main source of cost, the Uniform Patient Fee Schedule (UPFS) gazette, 
was updated according to that cycle.  
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4.5 Patient extraction 
4.5.1 Electronic database extraction 
Patients satisfying the selection criteria were screened from the hospital electronic 
database. The hospital had two electronic databases, viz. the Electronic Patient 
Records (EPR) system and the Medical Informatics (MI) database. The former is a 
unique independent database created for diagnosed cancer patients who attend the 
ROD and the latter is a universal database for all patients who attend the hospital. All 
patients at GSH have a hospital number and patients registered on the EPR database 
were assigned an RT number (hospital number for cancer patients). These two 
electronic records were screened for patients meeting the following criteria: 
registration date at the ROD between 1 April 2013 and 31 March 2015, a diagnosis of 
breast cancer and evidence of treatment with chemotherapy. Patients were extracted 
from the electronic database using key words such as „breast cancer‟ and 
„chemotherapy‟. 
The method of extracting patients from the database was developed in consultation 
with Dr Leon van Wijk (Oncology specialist), Ms. Wendy Bryant (Director of the MI 
Department, GSH) and Mr Kobus Botha (Developer of the EPR database). 
The patients diagnosed with breast cancer who attended the ROD at GSH were 
identified and selected for possible inclusion in the study. A list of breast cancer 
patients was extracted from the EPR database and collated with a list of patients 
extracted from the MI database. The extraction of patients from the EPR system was 
conducted in order to validate the MI patients‟ list.  
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4.5.2 Sampling 
A total of 1 024 patients were extracted from the electronic database. A random 
selection process was applied where 200 patients were selected. A random number 
generator was employed on excel spreadsheet. Patient folders were requested from 
the Radiation Oncology medical records at GSH. 
Missing folders were followed up once every month during the data collection period. If 
the folder was not found at all, another patient was selected from the random sample 
to replace the patient with a missing folder.  
4.6  Data collection 
Data on every patient were collected from the electronic patient records and the 
patient folders. The data collection approach is discussed in detail hereunder.  
4.6.1 Electronic database 
Breast cancer patients were identified from the electronic database. Patients treated 
with chemotherapy were filtered from the EPR database. A patient list was retrieved 
with the following information for each patient: 
 RT number; 
 registration date; 
 date of birth; 
 diagnosis; 
 stage of disease; and 
 treatment intent. 
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The list retrieved from the EPR was then used to extract full patient treatment history 
from the MI database. The following information was obtained for each patient from 
the MI database: 
 hospital identification number; 
 RT number; 
 medication history ; 
 outpatient visits; 
 inpatient hospitalisation data; 
 scans and imaging; and 
 laboratory tests history. 
 
4.6.1.1 Data extracted from electronic database of patient records 
The two electronic databases, i.e. the EPR and the MI databases were the primary 
sources of the following combined information: 
i. patient demographics, i.e. name, surname, hospital number, RT number; 
ii. medication profile which included the name of chemotherapy, date of 
issue, quantity issued, cost of each medicine; 
iii. support medicines which included the name of medicine, dose of 
medicine, cost of each medicine, date of issue; 
iv. laboratory tests which included the name of test, number of tests 
performed, date when test was performed; 
v. scans and imaging data which included the name of procedure, number 
of procedures performed, date when scan was performed; 
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vi. consultation visits which included scheduled and emergency visits, date 
of consultation, department where patient attended; and 
vii. inpatient hospitalisation data which included the date of admission, date 
of discharge, duration of stay, ward type and reason of admission. 
 
The information available in the electronic database was obtained from the relevant 
departments within the hospital. The laboratory tests were obtained directly from the 
National Health Laboratory Services (NHLS) database.  
The accuracy of the information in the database was reliant on the personnel who 
captured the data from the primary source. The data in the pharmacy system were 
captured by the pharmacy personnel (pharmacist, pharmacist intern, pharmacy 
assistant) and the consultation visits together with chemotherapy administration 
sessions were entered by the nurse personnel or receptionists at the ROD. There 
were some inconsistencies with the information in the pharmacy database e.g. cost of 
ondansetron 8mg tablets (6 tablets per pack) was recorded as R120.37 instead of 
R10.13. The price difference could be attributed to capture error or bulk pricing. This 
cost of R120.37 was identified out of 20 prices of ondansetron on the cost template 
and it was considered to be an outlier. Therefore, the price difference was attributed to 
be a capture error.  
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4.6.2 Folder data collection 
The researcher was trained by Dr L. van Wijk on how to extract and interpret 
information from patient folders. A list of RT numbers was compiled and presented to 
the Radiation Oncology medical records department for extraction of patient folders.  
A data collection form (Annexure 1) was used to obtain additional information from 
patient folders. The form was designed specifically for the study by the researchers 
and validated by the doctors at the ROD.  
The information necessary for the cost analysis was extracted from the patient folders 
and recorded. Folder data collection process began in March 2015 and ended in 
December 2015. An average of 45-60 minutes was required to collect the required 
information for each patient using the data collection form.  
4.6.2.1 Data extracted from the patient folders 
Patient medical folders were used as the secondary data source of patient 
information. The following were obtained from this data source: 
i. detailed patient demographics which included the date of birth, age at 
diagnosis, date of registration, stage of disease, weight, height, body surface 
area; 
ii. detailed clinical information which included the histological type of disease, 
comorbidity, intention of treatment, hormone receptor status;  
iii. medicines which included the name and dose of chemotherapy medicines, date 
of administration, dose and quantity of support medicines issued; 
iv. laboratory tests which included the name of test, number of tests performed, 
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date when test was performed, results of test; 
v. scans and imaging data which included the name of procedure, number of 
procedures performed, date when scan was performed, result of scan or 
radiological procedure; 
vi. consultation visits which included scheduled and emergency visits, date of 
consultation, doctor notes on the visit; and 
vii. adverse events data which included the date when event occurred associated 
emergency consultation, inpatient hospitalisation*, medication issued for the 
event, laboratory tests, scans and imaging. 
*Inpatient hospitalisation data which included date of admission, date of discharge, 
ward type and reason of admission. Not all admissions were recorded in the 
patient folder 
The accuracy of information recorded in the patient folders was subject to the 
attending doctor or nurse who recorded the above listed information and interpreted 
the results of tests or radiological scans. In some instances the histology and 
pathology test results of patients were not recorded. The results were obtained from 
the NHLS database to complete the data collection form.  
The data on the electronic database and the patient folders were found to overlap on 
several occasions. Data were collected from patient folders mainly to supplement 
missing and incomplete patient information on the electronic database and to verify 
the information retrieved from the electronic databases for the each patient. 
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4.7  Validation 
4.7.1 Diagnosis validation 
In order to validate the diagnosis of breast cancer for each patient, criteria were 
developed for this purpose. If the patient met any one of the following criteria, the 
diagnosis of breast cancer was confirmed: 
 diagnosis of breast cancer recorded in the patient folder; 
 medication history consisting of chemotherapy for breast cancer or 
evidence of chemotherapy administration of breast cancer chemotherapy; 
and  
 a record of radiology and laboratory tests specific to breast cancer 
diagnosis such as mammogram and breast biopsy. 
 
4.7.2 Chemotherapy dose calculation 
The dosage of chemotherapy medicines was calculated based on the patient‟s body 
surface area (BSA) (Boutayeb et al., 2010; Ferro et al., 2008). At GSH the consulting 
doctor calculated the relevant dosages. The pharmacist was responsible for checking 
the dosage as calculated by the doctor.  
The method for validating the dosage in patients‟ folders was developed and applied 
with respect to GSH treatment protocols. The patients recorded on the cost template 
had their BSA recalculated by using the patients‟ weight and height as recorded in the 
patients‟ folders and on the data collection form. The process was randomly done 
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during the folder data collection to recheck the BSA figures recorded by the doctors in 
the patients‟ folders. The recorded BSA was found to be consistent with the patient‟s 
weight and height. 
4.8 Sources of cost 
The costs used for the study reflected the cost to GSH. The main sources of cost were 
the Uniform Patient Fee Schedule (UPFS), MI database and time and motion studies. 
The sources of costs used in this study are further outlined below: 
i. the cost for medicines (chemotherapy and support medicines) was obtained 
from the JAC system through the MI database. This cost reflected the 
acquisition cost to GSH; 
ii. the cost data for laboratory tests was obtained from NHLS through the MI 
database. This reflected the cost to GSH for the laboratory tests; and 
iii. the cost for the following list of components was obtained from the UPFS 
Provincial Gazette for Western Cape, No. 7245, 27 March 2014; 
 medicine dispensing fee; 
 administration of chemotherapy, ambulatory procedure facility fee and 
professional fee; 
 scheduled outpatient consultation facility fee and professional fee; 
 emergency outpatient consultation specialist or nurse fee and facility fee; 
 inpatient hospitalisation cost, specialist professional fee and facility fee; 
 scans and imaging cost of test and facility fee; and 
 drawing of blood cost for laboratory test. 
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Time and motion studies were also used as a source of cost for the following: 
i. compounding cost for chemotherapy IV medicines; 
ii. administration of chemotherapy medicines, specialist and nurse cost; and 
iii. outpatient doctor consultation cost. 
 
4.8.1 Time and motion studies 
A standardised task list was developed with expert help from the oncology pharmacist. 
The task list was used to develop the timing process as well as assist in the designing 
of the form for recording captured times. An interim one week observation period was 
set aside before the actual data collection commenced. The observer utilised this time 
to familiarise herself with the routine and duties of the personnel under study. The 
observer used a digital stopwatch that displayed time in the units of hour, minute and 
second, for accurate capture of the time taken to complete a task. 
The time for each activity was multiplied by the per-minute salary (Oglesby et al., 
2009). The salaries of the pharmacists, doctors and nurses were derived from the 
annual estimates published by the Department of Public Service and Administration of 
South Africa (salary scales 2014).  
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4.8.1.1 Chemotherapy compounding time 
A form (Annexure 2) designed for the pharmacist tasks was used to record the 
captured times taken to perform the tasks.  The tasks were grouped into three stages 
according to the order of handling of a prescription by the pharmacist from the point a 
prescription is brought into the pharmacy to the point when it is signed off by the 
pharmacist as complete. The three stages were: 
Stage 1 – checking the validity of the prescription and capturing of prescription onto 
the JAC system; 
Stage 2 – assembling of chemotherapy products and consumables from the time it is 
picked from the shelf or fridge and taken to the aseptic unit; and 
Stage 3 – actual compounding or mixing of intravenous (IV) chemotherapy, labelling, 
final checking and signing off as complete. 
In some instances the pharmacist performed the stages of compounding process in 
batches i.e. subsequently checked several prescriptions, entered on the JAC system, 
and assembled products. In stage 3 each chemotherapy medicine type e.g. epirubicin 
was prepared in batches depending on the number of prescriptions available at that 
moment. For those tasks the time taken for all prescriptions was recorded and then 
divided by the number of prescriptions to obtain the time of processing one 
prescription. According to the method of costing, a pharmacist salary for level 3 
pharmacist was used because a pharmacist at this level was compounding at the time 
of data collection. 
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4.8.1.2 Chemotherapy administration time 
The process of chemotherapy administration was conducted by the nurses as an 
outpatient consultation. The time and motion study measured the time taken for the 
process of chemotherapy administration.  
A data collection form (Annexure 3) was designed to capture the time taken to perform 
the relevant tasks undertaken by the health care professionals during the process of 
administering chemotherapy. 
4.8.1.3 Doctor consultation time 
A data collection form (Annexure 4) was used to record the time for the consultation. 
The process of observing and recording the time taken by the doctor during 
consultation with the patient was developed and approved by the doctors in the ROD. 
In order to maintain patient confidentiality the observer was not present in the 
consulting room during the consultation. The doctor informed the researcher of the 
reason for consult. The time taken by the doctor for the consultation with the breast 
cancer patient was measured.  
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4.9 Cost components studied 
The cost components studied in this project represent the direct medical costs of 
managing breast cancer with chemotherapy as the mainstay of treatment. This section 
also details how the cost components were calculated. 
The cost components studied are listed below and further explained in detail: 
 chemotherapy medicines 
 support medicines; 
 chemotherapy administration; 
 consultation visits; 
 laboratory tests; 
 imaging and scans; 
 inpatient hospitalisation; and 
 adverse events 
 
4.9.1 Chemotherapy medicines  
The oncology pharmacy under the pharmacy department at GSH provided all the 
medication to the patients.  All intravenous chemotherapy infusion medicine bags were 
prepared at the oncology pharmacy.  
The cost of these medicines was derived from the cost on the TPL or the cost charged 
by an external supplier (HP04 2014 ONC, Department of Health website).  
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Medicines were sourced from an external supplier when out-of-stock from the 
registered provider for tender medicines. The cost of infusions bags, syringes, 
needles, normal saline and other pharmacy materials were charged as part of 
medicines cost. The cost was calculated automatically on the JAC system through the 
stored formulas when the dosage of medicine was entered. The commonly used 
treatment regimens for primary breast cancer chemotherapy are listed in Table 2 
below. Patient folders were assessed for any protocol adjustment or substitutions. No 
drug wastage was assumed (Maslove et al., 2014). At the end of each day, the 
pharmacist tallies the number of all the breast cancer patients who received the same 
regimen and divides the cost according to the proportion of resources utilised. 
 
The process of mixing chemotherapy medicines and preparing infusion bags for 
administration is conducted by a pharmacist. The pharmacist‟s professional time 
during this process of compounding does not seem to be accounted for in the cost 
presented in the UPFS. A component of cost called the compounding fee was 
developed in the study and determined by time and motion studies (refer section 
4.8.1). The compounding fee was added to the medicine cost and dispensing fee in 
two different scenarios, i.e. scenario 1 included the medicine cost plus dispensing fee 
and scenario 2 included the medicine cost plus dispensing fee plus compounding fee. 
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Table 2: Breast cancer chemotherapy regimens at GSH 
Chemotherapy 
regimen 
Dosage instruction per cycle 
(IV bolus) 
Duration of therapy 
 
FEC 
 
 
 5FU 500mg/m2   
Epirubicin 75-100mg/m
2
  
Cyclophosphamide 500mg/m
2 
 
 
Cycle repeated at 21 day intervals for 6 
cycles 
 
  
AC or EC 
 
 
 Adriamycin 60 mg/m2  
Cyclophosphamide 600 mg/m
2
  
OR 
 Epirubicin 100mg/m2  
Cyclophosphamide 600 mg/m
2 
 
 
 
Cycle repeated at 21 day intervals for 4 
cycles  
 
Same as for AC 
 
FEC-P or FEC-D 
 
 
 5FU 500mg/m2  
Epirubicin 75-100mg/m
2
 
Cyclophosphamide 500mg/m
2 
 
 Paclitaxel 175mg/m2   
OR 
 Docetaxel 75mg/m2 
 
 
Cycle repeated at 21 day intervals for 3 
cycles 
  
 
Cycle repeated at 21 day intervals for 4 
cycles 
 
 
EC-P or EC-D 
 
 Epirubicin 100mg/m2  
 Cyclophosphamide 600 mg/m2  
 
 
 Paclitaxel 175mg/m2   
 OR 
 Docetaxel 75mg/m2 
 
 
 
Cycle repeated at 21 day intervals for 3 
cycles 
  
 
Cycle repeated at 21 day intervals for 4 
cycles 
 
 
DC 
 
 
 Docetaxel 75mg/m2 
Cyclophosphamide 600mg/m
2
 
 
 
Cycle repeated at 21 day intervals for 4 
cycles 
 
 
Taxanes 
 
 
 Paclitaxel 175mg/m2 (cap dose 
at 330mg) 
 Paclitaxel 60mg/m2  
 
 Docetaxel 75mg/m2  
 
 
Cycle repeated at 21 day intervals  
 
Cycle repeated at 7 day intervals  
 
Cycle repeated at 21 day intervals for 6 
cycles 
 
A- Adriamycin, C-Cyclophosphamide, D-Docetaxel, E-Epirubicin, 5FU- 5-fluorouracil, P-Paclitaxel, m
2
 – 
per metre squared 
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4.9.2 Support medicines  
These were sourced on tender and therefore the TPL applied (HP09 2014 SD, 
Department of Health website). Medicine classes used as support medicines for 
chemotherapy treatment are listed in Table 3 below. 
Table 3: Support medicines classes for patients with breast cancer 
Medication category Example of medicines 
Analgesics Paracetamol, tramadol, morphine 
Anti-emetics Ondansetron, metoclopramide, granisetron 
Anti-inflammatories Ibuprofen, corticosteroids e.g. prednisone 
Anaemia prophylaxis  Ferrous sulphate, folic acid 
Antibiotics  Varies e.g. Co-amoxyclav, flucloxacillin, piperacillin tazobactam, 
amikacin 
Anti-fungals Nystatin 
Laxatives Liquid paraffin, sorbitol 70% solution, Senna 
 
Support medicines relating to breast cancer treatment with chemotherapy were 
included. Chronic medicines were excluded from the analysis. Only medicines issued 
during the episode of care period were included.  
A dispensing fee of all medicines was charged per day regardless of the number of 
prescriptions presented to the pharmacy. The dispensing fee was charged to the 
chemotherapy cost. In instances where support medicines were issued on a particular 
day without chemotherapy, the dispensing fee was charged as a cost of support 
medicines. A dispensing fee was billed per patient per day for all the prescriptions 
presented to the pharmacy at GSH.  
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4.9.3 Chemotherapy administration 
The cost due to the process of administering chemotherapy to the patient was 
accounted for. According to the UPFS the cost was classified under ambulatory 
procedures comprising of a professional fee and a facility fee component.  
The professional fee accounted for the time of specialists, nurses and other health 
care professionals involved in the treatment of the patient. The facility fee covered the 
cost of the environment for providing the service and materials used. A professional 
fee and facility fee were charged for every cycle that chemotherapy was administered 
to the patient. 
To determine the cost allocated for professional fee for scenario 2, a time and motion 
study was conducted during chemotherapy administration as described in section 
4.8.1.  
The time for nurses and doctors observed taking part during the process of 
chemotherapy administration was included in the cost. To avoid double counting on 
the final cost, only the professional fee (fee levied for doctors and nurses) was 
substituted with cost derived from the time and motion study. 
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4.9.4 Outpatient consultation visits 
Routine outpatient consultations during diagnosis, treatment with chemotherapy and 
follow-up were recorded with an ICD-10 and/or a description on the MI database.  
Only consultations conducted by a specialist in the ROD were considered. The 
consultation fee costs were derived from the UPFS. 
The cost of each visit was made up of the professional fee (specialist, doctors and 
other health care professionals) and facility fee. Total cost of consultation per patient 
was obtained from the sum cost of all visits during the episode of care.  
4.9.4.1 Scheduled visits 
Doctor consultations conducted in the ROD and Breast clinic at GSH were selected. 
The date of consultation was required to be within the study period and confirmed with 
the doctor‟s notes available in the folders. The reasons for consultation ranged from 
clinical examination, diagnosis, treatment planning, treatment assessment, adverse 
events management and follow-up care. 
4.9.4.2 Emergency visits 
These were outpatient visits that were not scheduled visits. Patients presented at the 
casualty ward with an emergency situation requiring urgent attention. With respect to 
breast cancer treatment, these could have been due to adverse events or 
complications of chemotherapy. Costing was conducted for the particular event 
thereof. Tasks undertaken during this visit were, but not limited to, nurses‟ time 
providing care, doctor consultation, medicines provided and laboratory tests 
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conducted. The information was obtained from the hospital database and patient 
folders. 
4.9.5 Laboratory tests 
The cost for laboratory tests consisted of cost of test (as listed on the MI database) 
and cost of drawing of blood by the nurse. The drawing of blood cost (obtained from 
the UPFS) was charged for each day laboratory tests were conducted. The drawing of 
blood cost consisted of nurses‟ time and materials used during the preparation of 
blood samples which were sent for testing.  
Routine full blood count (FBC) and platelet tests were conducted at each cycle before 
chemotherapy administration. Additional tests done to rule out other possible 
diagnoses and co-morbidities such as tuberculosis or Human Immunodeficiency Virus 
tests were not factored into the final cost (Evans et al., 1995).  
4.9.6 Scans and imaging 
Routine diagnostic tests included, but were not limited to, mammograms, chest X-
rays, ultrasounds, magnetic resonance infrared (MRI) and bone scans. Equilibrium 
Radio-Nucleotide Angiocardiography (ERNA) was exclusively for monitoring the 
cardiac toxicity which could potentially have been caused by anthracycline therapy 
(Shan et al., 1996). Total cost of scans was a sum of procedure cost and facility fee 
for all scans conducted. Unit cost of a scan procedure was available in the radiology 
code book (Annexure J of the UPFS Government Gazzette). The procedures were 
grouped into 5 price categories, i.e. Category A–E. The facility fee was also listed in 
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the UPFS. With the expert assistance of Dr L. van Wijk, the correct price was 
allocated to each procedure.  
Other procedures that are not directly related to treatment of breast cancer with 
chemotherapy, such as electrocardiogram (ECG) or colonoscopy, were excluded.  
4.9.7 Inpatient hospitalisation  
In this study the inpatient hospitalisation episodes were mainly for the management of 
adverse events or for chemotherapy administration for patients boarding in the day 
ward for convenience purposes when they are receiving chemotherapy the following 
day. 
The cost of inpatient stay was attributed to the adverse events cost if there was 
evidence of such an event in the patient folder.  Cost of hospitalisation due to surgery 
or radiation therapy was not included in the study 
4.9.8 Adverse events 
The costs associated with treating toxicity from chemotherapy were taken into 
account. For the purpose of this study, an adverse effect was defined as an additional 
condition or complication that occurred during the episode of care or immediately after 
treatment with chemotherapy. Clinical information available in the patient folders aided 
in the identification of the adverse events components. All patients were searched on 
the electronic database for an adverse effect related hospital admission. Patients 
found to have an episode of adverse events were recorded. The detailed information 
about the adverse event was obtained from the ward G7 hospital records. 
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The method developed to calculate costs relating to adverse events management 
included components such as medicines, doctor emergency consultations, laboratory 
tests and ambulatory services (Petterson et al., 2012). 
Where information was available the cost of adverse events had the following 
components: 
i. inpatient hospitalisation cost charged per day for the full length of stay. 
Hospitalisation cost was obtained by multiplying the cost of inpatient stay by 
the duration of inpatient stay. The cost of inpatient stay was charged as 
professional fee and facility fee per 12 hour intervals; 
ii. cost of support medicines plus dispensing fee; 
iii. cost of laboratory tests consisting of unit cost of test plus drawing of blood fee; 
and 
iv. emergency consultation cost consisting of cost of emergency professional fee 
plus facility fee. 
The cost of adverse events applied only to patients who had a record of serious 
adverse effect(s) during the episode of care. In this study the definition of a serious 
adverse effect was any unwanted or unexpected reaction requiring hospitalisation or 
emergency consultation caused as a result of treatment with chemotherapy. 
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4.10 Cost categorisation 
The cost of breast cancer treatment and associated adverse events was broadly 
categorised based on the following: 
i. stage on diagnosis i.e. I, II, III or IV based on Tumor-node-metastasis (TNM) 
staging (Davari et al., 2013); 
ii. early stage or late stage cancer. Early stage cancer i.e. stage I and II, and late 
stage being stage III and IV invasive disease (Pagano et al., 2012; Will et al., 
2000); 
iii. age 18-35 years, 36-50 years, 51-65 years or older than 65 years; 
iv. chemotherapy treatment approach, i.e. adjuvant, neo-adjuvant or palliative 
based on type of treatment and clinical assessment as recorded in the folders; 
v. primary or salvage therapy based on type of treatment and clinical guidelines; 
and 
vi. type of chemotherapy regimen used according to the GSH treatment protocol. 
 
Costs were categorised based on the clinical information obtained from the patient 
folders. Where information was not clearly stated in the folder, the clinical information 
available was used to categorise costs. Expert opinion was obtained, where 
necessary.  
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4.11 Cost template 
The costing template was developed using an Excel® 2010 spread sheet. All patients 
who met the inclusion criteria were entered into the spread sheet. The cost template 
provided information derived from MI and information recorded on the data collection 
form. The data recorded on the cost template represented all utilised resources and 
direct medical costs that were related to breast cancer treatment according to the 
study aim and objectives. The data fields which were developed for this cost template 
are presented in Annexure 5. The cost template included all the relevant costs for 
calculating the cost of breast cancer treatment for an episode of care. The cost 
components explained in section 4.9 above were used to quantify the direct medical 
costs of treating breast cancer. 
The second part of the cost template provided costs for management of adverse 
events. The cost components that contributed to the cost of treating adverse events 
are explained in section 4.9.8.  
Two scenarios of costs were created from the developed cost template, i.e. Scenario 1 
was created from costs obtained from the UPFS and Scenario 2 was created from 
costs obtained from the UPFS and the time and motion studies (Table 4). The same 
patients included in the cost template were used in the development of costs of 
treatment for Scenario 2 costs.  
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4.12 Cost calculation 
The cost per episode of care was calculated for each patient using data that were 
collected as mentioned earlier. The UPFS was the main source of cost whilst the time 
and motion studies provided an alternative cost for scenario 2 according to Table 4 
below. All cost components were added to give the episode of care cost scenario 1 
and 2. 
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Table 4: The summary for calculation of costs per patient 
Cost component Cost calculation 
Chemotherapy 
medicines  
 
 
 
 
 
 
 
 
 
 
Scenario 1:  
 cost of medicines per cycle which was summed to provide the total 
cost for all cycles  
+ 
 dispensing fee unit cost multiplied by the number of cycles 
Scenario 2:  
 cost of medicines + compounding fee (TM) + dispensing fee 
 
Support medicines 
 
Scenario 1 and 2: 
 cost of all support medicines  
+ 
 dispensing fee where applicable added (refer to section 4.9.2) 
 
Chemotherapy 
administration 
Scenario 1:  
 professional fee per cycle (UPFS) multiplied by the number of cycles  
+ 
 facility fee (UPFS) per cycle multiplied by the number of cycles 
Scenario 2:  
 cost for doctor and nurse‟s time per cycle per protocol (TM) 
+ 
 facility fee (UPFS) per cycle multiplied by the number of cycles 
 
Consultation visits 
 
 
Scenario 1:  
 cost of doctor consultation (UPFS) multiplied by the number of 
consultations during the episode of care 
+ 
 facility fee (UPFS) per consult multiplied by the number of 
consultations during the episode of care 
Scenario 2: 
 average cost of doctor consultation (TM) multiplied by the number of 
consultations during the episode of care 
+ 
 facility fee (UPFS) per consult multiplied by the number of 
consultations during the episode of care 
 
Laboratory tests 
 
Scenario 1 and 2: 
 sum of unit costs for each test conducted  
+ 
 drawing of blood fee calculated per each day laboratory tests were 
done (normally at every cycle of chemotherapy) 
 
Scans and imaging 
 
Scenario 1 and 2: 
 sum of unit costs for each procedure conducted  
+ 
 sum of facility fee (UPFS) for each procedure conducted  
UPFS- Uniform Patient Fee Schedule, TM- time and motion, Compounding fee- cost per dose of chemotherapy 
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4.13 Cost analysis 
4.13.1 Cost at patient level 
The developed cost template allowed for the cost of treatment of breast cancer to be 
calculated at patient level. All the cost components that formed part of the patient‟s 
care were added to give a total cost for each patient. 
4.13.2 .Cost per episode of care 
The following costs were calculated in the study: 
i. each cost component had a cost at patient level; 
ii. each cost component had a total cost for the study population, obtained by 
adding the cost for each patient; 
iii. total cost per episode of care for each patient, obtained by adding all cost 
components relevant for the patient; and 
iv. total treatment cost per episode of care for all patients in the study. 
 
4.13.3 Average cost  
The average cost of treating a breast cancer patient in this study was calculated. It 
was obtained by dividing the total cost of treatment by the number of patients in the 
study. Similarly, an average cost of each component per patient was calculated by 
dividing the total cost of each component by the number of patients who utilised the 
component. 
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4.14 Predictive model development  
A decision tree model was developed to predict the cost of breast cancer treatment 
with chemotherapy. The cost of breast cancer treatment was grouped based on the 
stage of cancer. The probabilities of being diagnosed with any of the 4 stages of 
breast cancer and of a patient on chemotherapy to complete their prescribed episode 
of care period were used in the decision tree. The costs of treatment were linked to 
the likelihood of these events occurring at GSH. The same sample of 200 patients 
used in the development of the method was used in the decision tree model. The cost 
per event was obtained by multiplying the cost for the particular outcome by the 
outcome probability. These costs were compared with the costs of treatment from the 
developed method. The cost per episode of care was used in this analysis.  
4.14.1 Model assumptions 
The model made the following assumptions: 
i. the patients‟ chemotherapy medicines did not change during the study period; 
ii. there were no adverse events or complications with chemotherapy treatment; 
and 
iii. resource use for all components were incurred at GSH. 
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4.15 Statistical analyses 
The SPSS statistical package (version 4) was used to perform all computations. 
Descriptive statistics were used for all variables. Continuous variables were 
summarised in descriptive terms stating mean, median, cost range and standard 
deviation. Both means and medians were used to present cost of treatment due to 
some outliers which made the means differ from the median. 
The Pearson‟s chi-square tests were conducted to test whether there was a significant 
relationship between the following treatment categories: (1) stage of breast cancer 
with treatment approach, (2) episode of care cost with treatment approach and (3) 
episode of care cost with chemotherapy regimen. P-values less than 0.05 were 
considered to be statistically significant.  
A multivariate analysis of variance (Wilks‟ lambda) was used to test whether there are 
differences between the means of the categorised costs of treatment. The Wilks‟ 
lambda test was used in this study due to the following; (1) the groups which were 
examined were unequal in size, (2) small sample sizes of subgroups, (3) the groups 
were independent and not related, and (4) the groups had different mean values. The 
Wilks‟ lambda statistic was recorded with a p-value and the degrees of freedom. The 
computed p-values for the tests were compared with the α-value of 0.05. When the p-
values were less than the α-value of 0.05, the tests conducted were considered to be 
statistically significant.  
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A multiple regression analysis was used to investigate the relationship between the 
cost of treatment of breast cancer and the predictor variables, i.e. clinical stage, age at 
diagnosis, status of treatment (complete or incomplete), protocol and treatment 
approach. The f-value and the regression coefficient of determination are presented in 
Table 33. 
4.16 Ethics 
Ethical approval of this study was obtained from the Research Ethics Committee of 
the University of the Western Cape (ref 14/9/48) and the Human Research Ethics 
Committee of the University of Cape Town, Faculty of Health Sciences (HREC ref 
824/2014). The letters of approvals are attached on Annexure 6. Additional approval 
was granted by GSH to conduct the study in the Radiation Oncology Department of 
the hospital. Patient confidentiality was maintained at all times. Patient records were 
only accessible to the researchers directly involved in the study, i.e. Prof P. Valodia 
and N. Guzha. Patient data and records collected were kept in a password secure 
computer and data collection forms were kept in a locked cupboard.  
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CHAPTER 5 
 
  RESULTS  
 
The main focus of this chapter is to illustrate the development of the methodology for 
costing of breast cancer treatment and the results obtained using the method 
developed. The predictive models and scenarios developed were also presented.  
5.1  Demographics 
Two hundred (200) patients diagnosed with breast cancer during the period of 2013-
2015 were enrolled in the study according to the inclusion criteria. Demographic 
information was validated based on the data extracted from the electronic system and 
the patient medical folders.  
Patients enrolled at the GSH Radiation Oncology department (ROD) were confirmed 
breast cancer patients. According to the information collected from the hospital 
electronic database, a total of 1 024 patients were registered by the ROD between the 
period 1 April 2013 to 31 March 2015. Of the patients diagnosed with breast cancer, 
67.58% were treated with chemotherapy either alone or in combination with surgery, 
radiotherapy and/or hormone therapy. During the process of data collection 36 folders 
were missing. The reasons for missing folders were either because the folder was in 
another ward, the patient had died or the folder was misplaced. A total of 428 patients 
who received chemotherapy were eligible for inclusion in the study. Of these patients, 
a sample of 200 patients was selected by random sampling.  
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1024 breast cancer patients extracted from electronic 
system 
 
 
332 non-chemotherapy patients 
 
 
692 breast cancer patients treated with chemotherapy 
 
 
264 excluded as per exclusion 
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-enrolled in a clinical trial 
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428 patients included in the study 
 
 
 
 
 
 
Figure 2: Patient selection 
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5.2  Patient clinical characteristics 
A data set of 200 patients was used for this analysis. Table 5 provides information on 
the characteristics of patients enrolled into the study.  
Our sample (n=200) represented various racial groups and patients were between the 
ages of 23 and 77 years. The mean age was 50 years (SD 11.6 years) and 66% of 
patients were above 45 years old. The various stages of breast cancer incidences are 
reported in Table 5. Of all the stages of breast cancer, the highest incidence (49%) 
was reported for stage II at the point of registration as reflected in Table 5. The lowest 
incidence (7%) was recorded for stage I breast cancer.  Of the patients, 55% 
presented with a pre-existing comorbidity at diagnosis and of these 27% presented 
with 2 or more co-morbid conditions. The most frequent comorbidities were heart 
diseases (71 patients), endocrine diseases (25 patients), arthritis and pulmonary 
diseases (16 patients each) and retroviral disease (10 patients). Other less common 
comorbidities were depression, eczema and epilepsy.  
The majority (84.5%) of the diagnosed breast cancers were invasive ductal 
carcinomas (IDC) with ductal carcinoma in situ also detected. Other unusual variants 
of breast cancer such as Paget‟s disease, mucinous and adenoid cystic carcinomas 
accounted for less than 2% of the diagnosed patients. Adjuvant chemotherapy was 
the most prescribed approach of chemotherapy treatment at GSH. Of the patients in 
the study, 61% had adjuvant chemotherapy while 30% had neo-adjuvant 
chemotherapy. Only 9% of patients received palliative chemotherapy treatment. 
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Table 5: Clinical characteristics of study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DCIS – Ductal Carcinoman in Situ, IDC – Invasive Ductal Carcinoma, LCIS – Lobular Carcinoma in Situ, ILC – 
Invasive Lobular Carcinoma. NOS – Not Otherwise Stated 
 
Prior to commencing chemotherapy treatment each patient‟s body surface area (BSA) 
was calculated. BSA is an important indicator of metabolic mass rather than weight 
alone in determining the dose of chemotherapy a patient should receive. The doctor or 
nurse calculated the patient‟s BSA at every cycle of chemotherapy to minimise under 
or over dosing of intravenous cytotoxic chemotherapy medicines. The average BSA in 
this study population was 1.83m2 (Universal average for women is 1.7m2) (Sacco et 
al., 2010). 
 
Patient characteristic  Number of patients 
(n=200) 
Population 
% 
 
Age at diagnosis 
18 - 35 
36 - 45 
46 - 65  
>65years 
 
22 
46 
113 
19 
 
11% 
23% 
56.5% 
9.5% 
Stage at diagnosis 
Stage I 
Stage II 
Stage III 
Stage IV 
 
14 
98 
65 
23 
 
7% 
49% 
32.5% 
11.5% 
Histology  
Ductal DCIS, IDC 
Lobular LCIS, ILC 
Paget‟s disease 
Mucinous 
Adenoma NOS 
Not mentioned 
 
169 
13 
1 
1 
1 
15 
 
84.5% 
6.5% 
0.5% 
0.5% 
0.5% 
7.5% 
Modality 
Adjuvant 
Neo-adjuvant 
Palliative  
 
123 
59 
18 
 
61.5% 
29.5% 
9% 
Comorbidity  
0 
1 
2 or more 
 
91 
55 
54 
 
45.5% 
27.5% 
27% 
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Each patient with breast cancer was tested for hormone involvement i.e. progesterone 
receptors, estrogen receptors and HER2, upon diagnosis of breast cancer. The result 
of each of the 3 tests was recorded in the patient folders. In some cases where the 
test result was missing or was not recorded in the patient folder, the test was recorded 
in the data collection form as missing. The missing test results for progesterone 
receptor (PR), estrogen receptor (ER) and HER2 were 6%, 3% and 4% respectively. 
When the results in Table 6 are translated to percentages, 50.5% of the tests 
conducted were positive for ER and 50% tested positive for PR. ER positive patients 
were prescribed tamoxifen. The positive and negative results of the HER2 tests were 
evenly distributed within the study sample, i.e. 33.5% positive and 34.5% negative. 
For the balance of the patients, 28% were equivocal (test in-between positive and 
negative) and 4% missing. Although 33.5% of the patients tested HER2 positive, 
trastuzumab was not available at GSH. Out of the 200 patients, there were 27 patients 
with a triple positive result and there were 39 patients with a triple negative result. 
Both groups of patients were treated with chemotherapy either as curative or palliative 
therapy. Furthermore, the patients with a triple positive or ER positive result were 
managed with hormone therapy in addition to chemotherapy. The cost of hormone 
therapy was not determined in this study as the focus was on chemotherapy cost. 
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Table 6: Results of the hormone receptor tests 
  Number of tests
1
 (n=200) 
Positive Negative Equivocal Missing 
PR 100 88 - 12 
ER 101 93 - 6 
HER2 67 69 56 8 
PR - progesterone receptor, ER - estrogen receptor, HER2 - human epidermal growth factor receptor 2 
1
Each patient had three tests done and each test result was recorded in the patient folder 
2
Number of patients whose tests were neither positive nor negative, it was reported as equivocal. 
 
The Eastern Cooperative Oncology Group (ECOG) scale of Performance Status (PS) 
was used to assess how breast cancer affects the daily abilities of the patient, and as 
an important factor in determining appropriate treatment and prognosis. When a 
patient was diagnosed with breast cancer the doctors performed a physical 
examination in order to score each patient according to the status of symptoms and 
functions with respect to ambulatory status and need for care.  
As seen in the patient folders, PS 0 means normal activity, PS 1 means some 
symptoms, but still near fully ambulatory, PS 2 means less than 50% active, and PS 3 
means more than 50% of daytime in bed, while PS 4 means completely bedridden. 
According to Table 7, 51.5% of patients were PS 0 which means that they were fully 
active and normal functioning upon diagnosis. As the patients progressed with 
chemotherapy treatment, it was noticed that some moved to PS 1 and PS 2. It was 
assumed that the transition in performance could have been due to disease 
progression or presence of adverse events to chemotherapy treatment. 
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Tumour grade measured how well the cancer cells resembled the normal cells. A low 
grade tumour means well differentiated, resembling normal cells and thus better 
prognosis. Table 7 shows that 5.5% of the patients had grade 1 tumours, 33% had 
grade 2 tumours and 42% had grade 3 tumours. There were 19.5% of folders with 
missing tumour grade information. 
Lymphovascular invasion measured the extent of spread of cancer cells to nearby 
lymph nodes. A positive (yes) result means that the likelihood of distant spread of 
cancer cells may be greater. Of the patients, 33.5% tested positive whilst 39.5% were 
negative. For the remaining 27%, the information was missing from the patient folders. 
The reason for the missing information in the folder could not be established. 
However, it was assumed that one patient is attended by different doctors and some 
doctors record all the results in the folders whilst others do not. It was also assumed 
that due to the busy nature of the hospital there was often not enough time to update 
all the laboratory results in the patient folders.   
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Table 7: Prognosis indicator statistics at GSH 
Prognostic indicator Number of patients (n=200) Percentage (%) 
 
PS score 
0 
1 
2 
3 
4 
X 
 
103 
77 
5 
2 
0 
13 
 
51.5% 
38.5% 
2.5% 
1% 
0% 
6.5% 
Tumor grade 
1 
2 
3 
X 
 
11 
66 
84 
39 
 
5.5% 
33% 
42% 
19.5%  
Lymphovascular 
invasion 
Yes 
No 
X 
 
 
67 
79 
54 
 
 
33.5% 
39.5% 
27% 
PS- performance status (Sørensen, J.B et al. 1993), X means unknown or missing or not recorded in patient folder. 
 
5.3 Cost components  
5.3.1 Cost of chemotherapy 
The cost of chemotherapy was calculated at patient level per each cycle of regimen 
received. The cost per cycle of chemotherapy varied for each patient depending on 
the type of regimen prescribed.  
Table 8: Cost per cycle of chemotherapy regimens at GSH 
Chemotherapy regimen Average cost per cycle Number of cycles 
prescribed, (n) 
 
FEC R615.77 6 
EC R587.05 4 
FEC-P R790.14 7 (3-4)1 
EC-P R718.93 7 (4-3)2 
P R874.76 6 
C-Cyclophosphamide, E-Epirubicin, F- 5-fluorouracil, P-Paclitaxel 
1
3 cycles of FEC and 4 cycles of P, 
2
4 cycles of EC and 3 cycles of P 
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The cost of chemotherapy medicines was R761 152.26 for the 200 patients. The 
dispensing fee was added to each patient for each day a prescription was handled at 
the pharmacy. The cost of chemotherapy and dispensing fee amounted to R801 
311.26 for the 200 patients. 
The three aspects of chemotherapy costs that were studied were the cost of 
medicines (chemotherapy), dispensing fee and administration of chemotherapy. All 
the individual costs were added to give the total cost related to chemotherapy use as 
shown in Figure 3. The cost of compounding of chemotherapy medicines by the 
pharmacist was determined by time and motion studies. The compounding fee was 
added to the method developed for scenario 2 as illustrated in Figure 4. 
The R761 152.26 cost of the intravenous chemotherapy medicines represented the 
cost to the hospital incurred by the 200 patients during the study period (Figures 3 and 
4). The dispensing fee of R36 per patient per prescription was 5% of the cost of 
chemotherapy medicines. The cost of chemotherapy medicines was 2.9 times more 
than the cost of administering the chemotherapy.  
The cost of administering chemotherapy to the 200 patients was R262 749. The cost 
consisted of a professional and a facility fee. The professional fee was 2.15 times 
more than the facility fee. According to the UPFS, the professional fee consists of the 
cost of the nurses‟ fee and the cost of other health care professionals involved in the 
care of the patient. The cost of administering chemotherapy was a fee charged for 
providing the service to the patient and equipment used.
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Figure 3: Component costs for chemotherapy as they appear in the model scenario 1 (n=200) 
 
 
Figure 4: Component costs for chemotherapy as they appear in the model scenario 2 (n=200)
 
R761 152.26 
Chemotherapy 
cost 
R40 159 
Dispensing fee 
R262 749 
Administration  
of chemotherapy 
cost 
 
R1 064 060.26 
Total cost of 
chemotherapy  
R761 152.26 
Chemotherapy 
cost 
R40 159 
Dispensing 
fee 
R44 671.54 
Compounding 
fee 
R262 749 
Administration 
of 
chemotherapy 
R1 108 671.80 
Total cost of 
chemotherapy 
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Table 9: Chemotherapy components for the treatment of breast cancer at GSH 
(n= 200)  
Cost component  Costs for 10-12 month period  
Cost (n=200) % 
(n=200) 
Average 
cost per 
patient 
SD Median Min-Max 
Chemotherapy 
and dispensing 
fee 
R801 311.26 75.3 R4 006.56 R1 635.67 
 
R3 880.81 
 
R544.82 – R10 653.39 
Administration of 
chemotherapy 
 
R262 749.00 24.7 R1 313.75 R335.46 
 
R1 404.00 R234.00 – R3 276.00 
Chemotherapy 
total cost 
R1 064 060.26 100 - - - - 
In the model for calculating the cost of treatment, other cost components relating to 
chemotherapy in the management of breast cancer were accounted for. Of the total 
cost, the cost components, i.e. chemotherapy, support medicines, consultation, 
laboratory tests, scans and imaging procedures accounted for 33.7%, 7.5%, 17.4%, 
14.1% and 27.3% respectively. All the cost components costs are summarised in 
Figure 7, Section 5.4.3.  
Table 10: Summary of other cost components studied for the treatment of 
breast cancer at GSH 
Cost 
component 
Costs for 10–12 month period  
Cost (n=200) % 
(n=200) 
Average 
cost per 
patient 
SD Median Min-Max 
Chemotherapy 
total cost 
R1 064 060.26
1
 33.7 - - - - 
Support 
medicines 
 
R235 425.67  
 
7.5 R1 177.13 R738.21 R1 089.87 R116.99 – R 7 385.48 
Consultation R549 562.00  
 
17.4 R2 747.81 R736.31 
 
R2 691.00 
 
R897.00 – R4 784.00 
Laboratory 
tests (routine) 
 
R445 247.98  
 
14.1 R2 237.43 R1 166.12 R1 997.01 R447.48  – R6 840.00 
Scans and 
imaging 
(routine) 
 
R860 582.00  
 
27.3 R4 302.91 R1 674.10 R4 233.00 R527.00 – R10 064.00 
Total cost R3 154 877.91 100 - - - - 
1
Cost derived from Table 9 and includes the following components: chemotherapy medicine, dispensing fee and 
administration of chemotherapy   
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5.3.2 Cost of chemotherapy regimens as per GSH protocol 
The chemotherapy medicines that were studied were categorised based on the type of 
chemotherapy regimen selected for the patient. The chemotherapy regimens were 
classified according to the identified patterns of prescribing (as seen in the patient 
folders) and the GSH breast cancer protocol provided. The GSH protocol had at least 
6 regimens of different chemotherapy combinations (Table 2, Section 4.9.1).  
In the study, it was found that 5 regimens were widely prescribed. The other regimen, 
i.e. cyclophosphamide and docetaxel was not used often probably due to cost and a 
high potential to cause adverse events. In the class of taxanes, paclitaxel was 
preferred as compared to docetaxel. According to the prices listed on MI database, 
paclitaxel 100mg injection for infusion costs R143.13 while docetaxel 80mg injection 
for infusion costs R825.78. Although the medical informatics database listed docetaxel 
on the price list, docetaxel was not used by any of the 200 patients in this study.  
The therapeutic regimen, FEC, prescribed every 21 days cycle for 6 cycles, was the 
most frequently prescribed regimen (48.5%) for patients across all disease stages. 
The EC-P combination was least prescribed in 3.2% of patients. 
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C-Cyclophosphamide, E-Epirubicin, F- 5-fluorouracil, P-Paclitaxel 
 
Figure 5: Number of patients who received chemotherapy regimens 
 
The average cost of each regimen used is illustrated (Figure 6). The costs obtained 
from scenario 1 were used in this analysis. The scenario definitions are in section 
4.12. The paclitaxel regimen (P) was the most expensive regimen of chemotherapy. 
The average cost per patient for P was R6 143.39. The most frequently prescribed 
regimen (FEC) was R5 115.37 per patient. The least expensive (R2 662.46) of all the 
regimens was the EC regimen. 
 
FEC, 97 
FEC-P, 51 EC, 42 EC-P, 3 
P, 7 
Other, 10 
Chemotherapy regimens (n=200) 
FEC FEC-P EC EC-P P
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C-Cyclophosphamide, E-Epirubicin, F- 5-fluorouracil, P-Paclitaxel 
 
Figure 6: Average cost per patient of each regimen used at GSH 
 
Table 11 shows the variation in cost of chemotherapy regimens, which were found to 
vary depending on the type of chemotherapy and dosage of medicines prescribed for 
each patient. The range of cost of each regimen was found to be fairly wide (refer to 
Table 11 for maximum and minimum cost per patient). This is because the recorded 
cost included both complete and incomplete protocols according to each patient‟s 
circumstances. About 14% of chemotherapy regimens at GSH were not completed as 
prescribed. The main reasons for discontinuation of chemotherapy were disease 
progression, toxicity (adverse events), patient refusal and death. 
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Table 11: Chemotherapy regimens as utilised by study population 
Chemotherapy 
regimen 
Number of 
patients, 
(percentage) 
Average cost 
per patient  
Minimum cost 
per patient  
Maximun 
cost per 
patient  
FEC 97 (48.5%) 
 
R3 827.50 R544.82 R6 808.57 
FEC-P 51 (25.5%) 
 
R5 115.31 R1 302.29 R9 758.47 
EC 42 (21%) R2 662.46 R633.04 R6 533.98 
EC-P 3 (1.5%) R4 778.81 R3 675.10 R5 801.08 
P 7 (3.5%) R6 143.39 R2 983.90 R10 653.39 
C-Cyclophosphamide, E-Epirubicin, F- 5-fluorouracil, P-Paclitaxel  
The average cost of treating a patient on the FEC regimen differed by 37% when 
compared to paclitaxel. The cost of FEC-P and the EC regimens were higher (25%) 
and lower (30%), respectively, than the standard FEC regimen.  
The prices of chemotherapy medicines obtained from the MI database were validated 
and checked for consistency. It was discovered that there were significant price 
variations for the same medicines, prescribed for the same patient, within the same 
episode of care and for the same dosage. Upon enquiry with the hospital pharmacy 
manager and the developer of the chemotherapy pricing system, the following reasons 
were given for the noted price variations. It was indicated that, (a) the chemotherapy 
medicines were prepared in batches and each patient was charged an average price 
for the same chemotherapy prepared in the batch on the particular day, and (b) the 
chemotherapy medicine prices were calculated based on the dosage of each patient 
according to the patient‟s BSA. 
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5.3.3 Cost of support medicines  
The cost of support medicines was relatively inexpensive. The average cost per 
patient was R1 177.13 (SD R738.21) for the entire episode of care. The electronic 
data provided were characterised by minor price variations which were largely 
accounted for due to capture error. It was assumed that the quantity of medicines 
issued was captured incorrectly as the JAC medicines system automatically calculated 
the price of medicines using the captured quantities. When calculated per patient, the 
most costly class of medicines was the antibiotics (given in some cases to treat 
neutropenia) and the least costly was the antiemetics. The TPL of medicines was 
used to validate the price of medicines. 
Table 12: The commonly prescribed medicines and their prices derived from the 
Medical Informatics (MI) and the Tender Price List (TPL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 The cost of betamethasone tablets and amikacin injection were not available on the TPL provided  
 
 
Medicine and pack size available 
 
MI  TPL  
Metoclopramide 10mg x 30 tablets 
 
R1.99 R1.58 
Prednisone 5mg x 30 tablets 
 
R2.72 R3.25 
Betamethasone 500µg x 48 tablets 
 
R124.05 Missing
1
  
Ondansetron 8mg in 1 x 4ml injection 
 
R6.75 R6.75 
Ibuprofen 200mg x 21 tablets 
 
R1.50 R2.12 
Hyoscine n-butylbromide 10mg x 10 tablets 
 
R4.90 R5.84 
Paracetamol 500mg 10 x 10 tablets 
 
R11.03 R11.28 
Folic acid 5mg x 28 tablets 
 
R1.78 R1.28 
Tramadol 50mg x 80 capsules 
 
R20.45 R22.76 
Amikacin 500mg in 2ml injection  R16.96 Missing 
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5.3.4 Cost of laboratory tests 
The number of laboratory tests that were conducted routinely were 6 177 and 116 
tests were conducted due to adverse events. The laboratory tests were conducted as 
a standard procedure at each cycle before chemotherapy administration and when the 
patient presented with adverse events. The average cost of laboratory tests per 
patient was R2 226.24 for the episode of care. The laboratory tests that were 
conducted outside the study site were not included in the analysis. A total number of 6 
patients had all or some tests conducted privately. The maximum cost of laboratory 
tests per patient was R6 840.06 and the minimum cost per patient was R447.48. The 
average cost for laboratory tests conducted for adverse events management was 
lower (R551.82) than the average cost (R2 237.43) for the tests done during routine 
treatment period. This was because the adverse events tests were conducted during 
the period (1-2 months) when the adverse events occurred whilst the routine tests 
were greater in number and conducted over a longer period of time (10-12 months). 
Table 13: Cost of laboratory tests (routine and adverse events) 
Category  Number of tests  Cost of all tests Average cost per 
patient  
 
Routine laboratory 
tests 
6 177 
(n=199) 
R445 247.98 
 
R2 237.43 
SD R1 166.12 
(R447.48 – R6 840.06) 
 
Laboratory tests for 
adverse events 
management 
116 
(n=10) 
R5 518.14 R551.82 
SD R589.14 
(R108.76 – R1 642.11) 
 
Total of all tests 6 293 
(n=199) 
R450 766.12 R2 265.16 
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A list of laboratory tests that appeared on the MI database and patient folders was 
compiled and tabulated below (Table 14).  
Table 14: Laboratory tests conducted for breast cancer patients at GSH 
 
Test  Procedure  Indication 
  
Blood tests FBC 
Platelet 
Standard assessment for 
bone marrow metastasis 
 
Liver function tests  Total bilirubin 
Albumin 
Alanine transaminase 
Aspartate transaminase 
Alkaline phosphatase 
Gamma-glutamyl transferase 
 
Baseline tests to assess 
state of liver functioning 
and involvement 
Renal function tests Creatinine  
Calcium  
Urea 
Electrolytes 
 
Assessment of possible 
obstructive renal symptoms 
Menopause  Follicle stimulating hormone 
Luteinising hormone 
Estradiol  
  
Assessment of menopausal 
status 
Histology  ER (estrogen receptor) 
PR (progesterone receptor) 
HER2 (human epidermal 
growth factor receptor 2) 
 
Determination of tumour 
type and grade 
 
5.3.5 Cost of scans and imaging 
As shown in Table 15, the cost of all scans and imaging procedures relating to both 
breast cancer treatment and management of adverse events was R871 843. The cost 
was measured over a period of each person‟s episode of care after the primary 
diagnosis of breast cancer. The cost per patient (R4 302.91) was calculated as an 
average. The facility fee represented 48% of the cost and the remainder included 
professional or procedure costs.  
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Table 15: Cost of scans and imaging procedures (routine and adverse events) 
Category  Number of procedures Cost of 
procedures 
Average cost per 
patient 
 
Routine scans 1477  
(n=200) 
R860 582.00 R4 302.91 
SD R1 674.10 
(R527.00 – R10 064.00) 
 
Scans for adverse 
events management 
24 
(n=7) 
R11 261.00 
 
R1 608.71 
SD R1 800.58  
(R527.00 – R5 048.00) 
 
Total of all tests 1 501 
(n=200) 
R871 843.00 R4 359.22
1
 
1. The average cost per patient of all tests is calculated by dividing cost of procedures with 
200 patients who had routine procedures and 7 of which had adverse events.  
The facility and procedure fees for scans and imaging are listed in Table 16. The 
UPFS grouped the scans and imaging procedures in categories according to the 
facility and procedure costs. When the cost of routine tests is combined with cost of 
adverse events, the average cost of all tests was found to be more than the average 
cost of routine tests alone by 1.3%.  
Table 16: Scans and imaging procedures conducted at GSH 
UPFS category Procedure Facility fee Procedure fee 
 
B Mammogram 
US breast 
US abdomen/ liver/ pelvis 
Chest xray 
CT scan body 
 
R200 R327 
C Bone scan 
US guidance biopsy 
 
R463 R800 
D US abdomen and pelvis 
CT scan head 
 
R925 R1 599 
Unknown group
1
 ERNA 
 
R576 R286 
CT – computed tomography, ERNA – Equilibrium Radio-Nucleotide Angiocardiography, US - ultrasound 
1
 ERNA cost was not available in the UPFS gazette but obtained from the hospital electronic system. 
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The UPFS facility fee was an integral part of obtaining the cost of each component. 
The costs of providing the facility for the services that were rendered at GSH to the 
patients are listed in Table 17. The costs were fixed and charged for every patient who 
received the particular service.  
Table 17: UPFS facility fees 
UPFS component Tertiary hospital unit cost  
Dispensing fee per day R36 
Administration of chemotherapy R87 
Outpatient consultation R95 
Emergency outpatient consultation R192 
Inpatient General ward per every 12 hours R774 
Scans and imaging 
   Mammogram 
   CT scan of abdomen and pelvis 
Varies depending on type of procedure 
R200 (minimum fee) 
R925 (maximum fee) 
Drawing of blood R31 
Provincial Gazette for Western Cape No. 7245, 27 March 2014  
CT – computed tomography 
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5.4 Developed cost method: Cost calculation 
The development of the costing method was fully explained in Chapter 4. The costing 
method included data from Medical Informatics (electronic data) and from the patients‟ 
folders to ensure a complete data set. The results were presented as different 
scenarios depending on the different sources of costs. For the purpose of this study all 
costs are reported for the time period 2013 to 2015.  
The costs obtained from the cost components were used in the development of the 
cost model. The model comprised of cost of chemotherapy and the associated cost 
components related to breast cancer management.  When developing the cost model 
an incremental approach to costing was followed. 
The starting point was understanding the cost of the chemotherapy medicines. The 
cost of chemotherapy medicines was categorised according to the 5 main regimens 
available at GSH. This cost of each regimen was obtained at patient level. 
To the chemotherapy medicines, a dispensing fee of R36 was added. This was added 
according to the format explained in Section 4.9.2. 
The support medicines were screened for relevance to the chemotherapy treatment by 
confirming the indication within the patient folders. The costs of support medicines and 
their respective dispensing fees were added to the model. 
Thereafter, professional fees and facility fees obtained from the UPFS were added to 
each patient according to their individual history as collected from the MI and patient 
folders.  
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The professional and facility fees were for the following components: administration of 
chemotherapy, laboratory tests, doctor consultation, and scans and imaging 
procedures.  
The sum of the cost components mentioned above resulted in the cost for episode of 
care per patient and the total cost of treatment of breast cancer with chemotherapy at 
GSH.  
The professional fees for the administration of chemotherapy and doctor consultation 
were substituted with costs obtained from time and motion studies to give a second 
scenario of the cost. Furthermore, time and motion studies were utilised to calculate 
the cost of compounding of chemotherapy by the pharmacist. The aforementioned 
resulted in the cost of an episode of care for scenario 2. 
Thereafter, information for patients who had adverse events to chemotherapy 
treatment was collected and added to the model.  
5.4.1 Cost of components 
The detailed costs of different components of treatment, following the primary 
diagnosis are displayed in Table 9 and 10. The highest component cost for the 200 
patients was incurred for scans and imaging at a cost of R860 582. Support medicines 
were the least costly of all the cost components. The cost of all support medicines for 
all the 200 patients was R235 425.67. When evaluating the cost per patient for each 
component, the main cost drivers were the cost of scans and imaging and the cost of 
chemotherapy. The different cost components studied accounted for varying 
proportions of the total cost as shown in Figure 7.  
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The figure illustrates the total cost of each component as calculated for all 200 patients. The total cost sums up all 
the episode of care costs for each of the 200 patients. 
Figure 7: The cost components of breast cancer treatment (n=200) 
5.4.2 Cost of breast cancer per episode of care 
The cost of treating breast cancer for the episode of care based on the variables and 
scenarios taken into consideration ranged from R12 664.76 to R16 259.72 per patient 
(Table 19). 
The study population of 200 patients was made up of patients who completed their 
treatment cycles for chemotherapy and patients who did not complete due to reasons 
explained in Section 5.3.2. 
Table 16 indicates the total cost of treatment for patients who completed treatment 
during their episode of care and those patients who did not complete treatment. Of the 
sample of 200 patients, the patients who completed treatment were 6 times more in 
number than the patients who did not complete their treatment with chemotherapy.  
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The total direct medical cost of treatment for 200 patients was R 3 154 877.90 (Table 
18). The cost was calculated at patient level for a period of 10 - 12 months post 
diagnosis. The cost included all cost components for the management of breast 
cancer as studied in this research. Cost of diagnosis prior to enrolment at ROD was 
not included because the study excluded patients with an unconfirmed diagnosis 
and/or a negative diagnosis of breast cancer (Groot et al., 2006). The average cost of 
treatment for the episode of care period was R15 774.39 per patient (Table 19).  
Table 18: The proportion of total costs by complete and incomplete 
chemotherapy treatment 
 Number of 
patients (n) 
 
Percentage 
(%) 
Total cost 
(episode of 
care
1
) 
All patients 200 
 
100% R3 154 877.90 
Patients who completed 
treatment 
173 86.5% R2 812 929.40 
Patients who did not complete 
treatment 
27 13.5% R341 948.50 
1
 The method included the costs associated with chemotherapy treatment and excluded cost associated with 
radiotherapy, surgery or hormonal treatment 
 
5.4.3 Cost of management of breast cancer 
The average costs of managing a patient diagnosed with breast cancer at GSH are 
reported in Table 19. The average cost was calculated based on each individual‟s 
duration of treatment. The average costs for patients who completed and who did not 
complete treatment were categorised separately. The average cost of treating a 
patient who manages to adhere to prescribed chemotherapy for the full duration of 
treatment was R16 259.72.  
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The cost of a small proportion (13.5%) of the study sample that did not complete the 
prescribed treatment was on average R12 664.76 per patient. The combined average 
cost of all the 200 patients in the study was R15 774.39.  
The complete protocol cost allows the funder of care to estimate maximum budget for 
treatment of breast cancer whilst the incomplete protocols allows for the identification 
of true circumstances surrounding the treatment of breast cancer. The average and 
median per patient costs based on whether the protocol was completed or not are 
displayed in Table 19 below. 
Table 19: Average cost of management of breast cancer per patient at GSH 
 Average cost per 
patient 
Median cost per 
patient 
Total cost 
Approximately 10–12 month period 
Complete protocol 
(n=173) 
R16 259.72 
SD R6 077.37 
 
R15 551.00 R2 812 929.40 
Incomplete protocol  
(n=27) 
R12 664.76 
SD R6 417 75 
 
R12 252.07 R341 948.50 
All patients  
(n=200) 
R15 774.39 
 
 
R15 295.68 R3 154 877.90 
Adverse events 
(n=27) 
R7 782.53 
 
 
R6 870.21 R210 128.37 
 
5.4.4 Total cost of breast cancer 
The total costs associated with breast cancer treatment are presented in Table 20. 
The costs are expressed as costs per episode of care calculated from the number of 
breast cancer patients treated with chemotherapy with different scenarios of cost. The 
cost of chemotherapy, administration of chemotherapy and consultation were 
presented in 2 scenarios.  
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The total cost of treatment was also presented as 2 different scenarios. The scenario 
definitions were explained in full in Section 4.12. 
Scenario 1: Cost of components calculated with the UPFS fees as the main source of 
cost  
Scenario 2: Cost of components calculated with UPFS fees and costs obtained from 
the time and motion studies. 
The average cost per patient of scenario 1 was R1 442 (9%) more than the cost of 
scenario 2. It appears that the UPFS costs are more than the costs determined based 
on the actual time of consultation and administration of chemotherapy. However, a 
decent comparison can be drawn when the sample sizes in the study are increased 
and other types of cancers are also taken into consideration. Statistical tests were 
conducted on the total costs of breast cancer obtained from scenario 1 and scenario 
2, based on the study sample. The two scenarios for the total costs of breast cancer 
were found to be statistically significant (p<0.001) using the Wilks‟ Lambda test. The 
results of the other tests conducted on the total cost of breast cancer are attached on 
Annexure 7.  
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Table 20: Total cost of scenario 1 versus scenario 2 for the treatment of breast 
cancer 
Cost component Total cost for 10–12 months 
period  
Average cost per patient   
Scenario 1 
 
Scenario 2 Scenario 1 Scenario 2 
Chemotherapy cost 
 
SD 
Median 
R801 311.26 
 
R1 635.67 
R3 880.81 
 
 
R845 982.80 
 
R1 667.14  
R4 120.33 
R4 006.56 
 
R3 880.81 
R1 635.67 
 
R4 229.91 
 
R4 120.33 
R1 667.14 
Administration of 
chemotherapy 
 
SD 
Median 
 
R262 749.00 
 
R335.46 
R1 404.00 
 
 
R150 158.02 
 
R199.65  
R822.02 
 
R1 313.75 
 
R335.46 
R1 404 
 
 
 
R750.79 
 
R199.65 
R821.03 
 
Consultation 
 
SD 
Median 
R549 562.00 
 
R736.31 
R2 691.00 
 
R329 036.66 
 
R427.42  
R1 612.07 
R2 747.81 
 
R2 691 
R736.31 
 
R1 645.18 
 
R1 612.07 
R427.40 
All components
1
 (n=200) R3154 877.90 
 
R2 866 433.11 R15 774.39 
 
R14 332.17 
 
1
Total cost of all components included all other components of costs studied 
The average cost per patient for administering chemotherapy was R1 313.75 for 
scenario 1 and R750.79 for scenario 2. According to the time and motion study 
results, it took an average of 16.87 minutes of nurses‟ time to administer 
chemotherapy. The time, however, varied according to the regimen of chemotherapy 
received. According to Table 21, it took an average of 19.54 minutes to administer 
FEC, 13.76 minutes for EC and 17.29 minutes for P. The EC regimen took less of the 
nurses‟ time than the P regimen. The single dose regimen P took 3.53 minutes more 
than the FEC regimen because the infusion rate of the P regimen was slower than the 
FEC regimen.  
The costs of scenario 2 for administration of chemotherapy and doctor consultation 
were found to be less than the cost obtained with scenario 1. The chemotherapy cost 
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showed an increase in cost from scenario 1 to scenario 2. The cost of compounding of 
chemotherapy increased the total cost of chemotherapy by 5.3%. The pharmacists‟ 
time determined in this study reflected the actual cost incurred by the hospital during 
compounding of these chemotherapy medicines. It took an average of 9.76, 6.74 and 
4.97 minutes to compound FEC, EC and P, respectively (Table 21).  
 
Table 21: Time and motion study results 
Task being measured Average time per cycle (min) Average cost per cycle  
Compounding of chemotherapy Pharmacists’ time  
FEC 9.76 R44.16 
EC 6.74 R30.49 
P 4.97 R22.50 
Consultation  Doctors’ time  
First visit 20.50 R114.21 
Follow-up 12.14 R67.61 
Administration of chemotherapy Nurses’ time  
FEC 19.54 R38.48 
EC 13.76 R27.10 
P 17.29 R34.05 
Administration of chemotherapy Doctors’ time  
Updating patient folder/ responding 
to query 
1.32 R7.36 
 
5.5 Cost categorisation 
The cost of breast cancer treatment was categorised according to clinical stage, age 
at diagnosis, treatment approach and type of therapy as presented below (Tables 22, 
23, 24 and 25). 
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5.5.1 Cost of breast cancer based on clinical stage 
The cost of each component was determined at patient level. The presented costs 
include the costs of all patients despite the fact that the prescribed protocol of 
chemotherapy was complete or not. The cost per treated patient with stage I disease 
was R13 646.45, stage II was R15 095.71, stage III was R16 871.01 and stage IV was 
R16 862.29, as illustrated in Table 22.  
An analysis of the stage at diagnosis revealed that the breast cancer patients who 
presented with stage III and IV had the highest cost of treatment.  
The median costs were R13 237.48, R14 563.21, R16 296.85 and R15 684.84 for 
stages I, II, III and IV breast cancer respectively. The median costs showed an 
increasing trend in cost as the stage of breast cancer increases. When the ranges of 
the four stages were compared, stage IV had the highest minimum cost (R5 867.43) 
on the range and stage II had the lowest minimum cost (R3 480.81). The widest range 
incurred was for stage III. 
Table 22: Cost of treatment per stage of breast cancer for all patients 
Stage at 
diagnosis 
Total cost per stage  
 
Average cost 
per patient per 
stage 
Range 
I R191 050.34 (n=14) 
 
R13 646.45  R5 611.08 – R24 419.35 
II R1 479 379.41 (n=98) 
 
R15 095.71 R3 480.81 – R37 705.02 
III R1 096 615.45 (n=65) 
 
R16 871.01 R3 922.06 – R38 627.40 
IV R387 832.70 (n=23) 
 
R16 862.29 R5 867.43 – R36 569.94 
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The total cost of treating early stage cancer was R1 670 429.75 and late stage cancer 
was R1 484 448.15. In this study early stage breast cancer was stages I and II 
disease while late stage breast cancer was stages III and IV disease. The Wilk‟s 
Lambda test found significant difference in cost between stage I and III, stage I and IV 
and stage II and III (p<0.001). However, there was no statistical significance observed 
between stages I and II and stages III and IV (p>0.05). As shown in figure 7, the 
variances of each stage of breast cancer were plotted using the one-way multivariate 
analysis of variance test (ANOVA).  
An overlap of the variances and confidence intervals of stages of breast cancer 
mentioned above resembled the presence of statistical significant differences 
(X2=491.77; df=9; p<0.001). The letters a, b and c in Figure 8, denote stages of breast 
cancer that are statistically significant and those that are not significant. The vertical 
bars with different letters, i.e. a and c or a and b, show statistical significance of cost 
between the respective stages. However, similar letters, i.e. a and a or c and c, show 
insignificant relationship. 
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Figure 8: The Wilk’s Lambda test for statistical significance differences of cost 
between the stages of breast cancer 
 
5.5.2 Cost of breast cancer based on age at diagnosis 
The patients were grouped into their respective age groups despite their type of 
chemotherapy received or the severity of their cancer. The highest incidence (113 
patients) of breast cancer occurred in the 46-65 years age group whilst the lowest 
incidence (19 patients) occurred in the oldest age group, i.e. greater than 65 years old. 
The widest range of cost (R36 885.80) was incurred for the second oldest group.  
The cost of treatment per age group is displayed in Table 23. The reported differences 
of the average costs per patient in each age group were found to be not statistically 
significant following a Wilk‟s Lambda test (p=0.15).  
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Table 23: Cost of treatment per age group 
 
 
5.5.3 Cost of breast cancer based on treatment approach 
The study population was tested for variation of cost based on the treatment approach 
as reported in Table 24. The results of this section showed that the most prescribed 
(62% of patients) type of treatment was adjuvant chemotherapy. The cost of treatment 
per patient with neo-adjuvant chemotherapy was greater than the cost of treatment for 
both adjuvant chemotherapy and palliative therapy. There were, however, small 
differences between the treatment approaches for the cost per patient as shown in 
Table 24.  
Table 24: Cost of treatment per treatment approach 
 
 
 
 
 
Age at diagnosis Cost per age group Cost per patient per 
age group 
Range 
18 – 35 (n=22) R358 815.97  
 
R16 309.82 R5 635.30 – R33 232.21 
36 – 45 (n=46) R737 405.26  
 
R16 030.59 R4 047.22 – R40 932.99 
46 – 65 (n=113) R1 782 553.28  
 
R15 774.81 R2 821.81 – R39 076.16 
>65 (n=19) R280 463.23  
 
R14 761.22 R6 345.75 – R22 294.32 
Treatment approach Cost per modality  Cost per patient 
per modality  
Range 
Adjuvant  R1 902 382 (n=123) 
 
R15 466.52 R2 618.81 – R40 779.16 
Neo-adjuvant  R979 908 (n=60) 
 
R16 331.80 R5 236.95 – R33 566.84 
Palliative  R272 587.50 (n=17) 
 
R16 034.56 R5 867.43 – R32 715.31 
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5.5.4 Cost based on primary and salvage therapy 
Cost of treatment of breast cancer was classified based on primary and salvage 
treatment. Only 2% of the patients entered in the study had salvage therapy. Salvage 
therapy is given after the cancer has relapsed following treatment with standard 
therapy. 
Table 25: Cost of treatment per primary and salvage therapy 
 Number of patients (%) Cost of protocols 
Primary
1
 200 (100%) R761 152.26 
Salvage 
2
 4 (2%) R20 334.04 
Total
3
 n/a R781 486.30 
1
All 200 patients were treated with primary  
2
Cost of treatment of recurrent episode of disease only 
3
Total cost is the sum of all recorded episodes of treatment (primary plus salvage). Minimum number of episodes 
per patient recorded was 2. 
 
 
5.6 Combined categorisation of costs 
The categories of costs that were studied were further analysed in order to understand 
their relationship with each other with respect to costs and prescribing patterns at 
GSH. 
5.6.1 Treatment approach versus stage of breast cancer 
Table 26 illustrates the relationship between the stage of breast cancer and the 
treatment approach selected for the patient. The trend discovered was that all patients 
diagnosed with stage I cancer were treated with adjuvant chemotherapy. The majority 
(87.8%) of stage II patients were treated with adjuvant chemotherapy whilst a few 
(11.2%) were prescribed neo-adjuvant chemotherapy.  
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The advanced stage cancer, i.e. stage III and IV showed that neo-adjuvant and 
palliative, respectively, were the treatments of choice. Overall, adjuvant chemotherapy 
was the mostly prescribed type of treatment with 123 out of 200 patients receiving this 
approach of treatment. The Pearson‟s Chi-Square test indicated a significant 
association between stage of breast cancer and the approach of treatment 
(X2=184.68; df=6; p<0.001). See Chi-Square test results in Annexure 7. 
Table 26: Treatment approach versus stage of breast cancer  
 Treatment approach Total  
% Adjuvant Neo-
adjuvant 
Palliative  
Clinical 
stage  
I Count 
% within CS I 
14 
100% 
0 
0% 
 
0 
0% 
14 
100% 
II Count 
% within CS II 
86 
87.8% 
11 
11.2% 
 
1 
1% 
98 
100% 
III Count 
% within CS III 
18 
27.7% 
46 
70.8% 
 
1 
1.5% 
65 
100% 
IV Count 
% within CS IV 
5 
21.7% 
3 
13% 
 
15 
65.2% 
23 
100% 
Total   Count 
% within CS all 
123 
61.5% 
60 
30% 
 
17 
8.5% 
200 
100% 
CS – Clinical stage 
 
5.6.2 Episode of care cost versus treatment approach 
The episode of care cost per patient was plotted against the type of treatment 
prescribed for each patient. The most prominent feature observed across all 
modalities is that the average cost of an episode of care falls between R14 001–R18 
000. The data also shows that most patients received adjuvant chemotherapy 
(61.5%), followed by neo-adjuvant (30%) and palliative therapy (8.5%).  
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The Pearson‟s Chi-Square test could not identify any significant differences between 
the cost categories (X2=14.350; df=10; p=1.58). See Chi-Square test result in 
Annexure 7.  
 
 
Figure 9: The episode of care cost against treatment approach 
5.6.3 Episode of care cost versus chemotherapy regimen 
The distribution of episode of care costs were analysed against the chemotherapy 
regimens prescribed at GSH. It was found that 52,6%, 51% and 42,9% of patients, 
who were prescribed with the regimens FEC, EC and P respectively, had a total 
episode of care cost within the range R14 001 to R18 000 per patient. The episode of 
care cost for patients prescribed the regimen FEC-P and EC-P were in the ranges 
R10 001 to R14 000 and R18 001 to R22 000, respectively per patient.  
6001-
10000
10001-
14000
14001-
18000
18001-
22000
22001-
26000
26001-
30000
Ajuvant 6 32 58 21 5 1
Neo-adjuvant 2 11 29 16 2 0
Palliative 1 6 7 0 3 0
0
10
20
30
40
50
60
70
Number of 
patients 
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The patients who had an episode of care cost within the lower ranges of cost were 
found to have not completed their treatment with chemotherapy. Only one person 
prescribed FEC had an episode of care cost in the highest range R26 001 to R30 000. 
This patient was in stage IV of breast cancer and was being managed with palliative 
chemotherapy. Overall, the most frequently prescribed regimens were FEC, EC and 
FEC-P. Table 27 illustrates the distribution of numbers of patients within the 
categories of episode of care costs utilising the listed regimens. The highlighted 
regions in Table 27 show the highest cost ranges for the episode of care for the 
particular chemotherapy regimen. The Pearson‟s Chi-Square test identified significant 
differences between the cost categories (X2=52.34; df=20; p<0.000). See Chi-Square 
test results in Annexure 7. 
Table 27: Episode of care cost versus chemotherapy regimen 
  Episode of care cost (Rand) Total  
Regimen   6000-
10000 
10001 -
14000 
14001 -
18000 
18001 - 
22000 
22001 -
26000 
26001 - 
30000 
FEC Count 
% within FEC 
% of total 
2 
2.1% 
1% 
19 
19.6% 
9.5% 
51 
52.6% 
25.5% 
21 
21.6% 
10.5% 
3 
3.1% 
1.5% 
1 
1% 
0.5% 
97 
100% 
48.5% 
EC Count 
% within EC 
% of total 
1 
2% 
0.5% 
8 
15.7% 
4% 
26 
51% 
13% 
12 
23.5% 
6% 
4 
7.8% 
2% 
0 
0% 
0% 
51 
100% 
25.5% 
FEC-P Count 
% within FEC-P 
% of total 
6 
14.3% 
3% 
21 
50% 
10.5% 
14 
33.3% 
7% 
0 
0% 
0% 
1 
2.4% 
0.5% 
0 
0% 
0% 
42 
100% 
21% 
EC-P Count 
% within EC-P 
% of total 
0 
0% 
0% 
0 
0% 
0% 
0 
0% 
0% 
2 
66.7% 
1% 
1 
33.3% 
0.5% 
0 
0% 
0% 
3 
100% 
1.5% 
P Count 
% within P 
% of total 
0 
0% 
0% 
1 
14.3% 
0.5% 
3 
42.9% 
1.5% 
2 
28.6% 
1% 
1 
14.3% 
0.5% 
0 
0% 
0% 
7  
100% 
3.5% 
Total  Count 
% within A 
% of total 
9 
4.5% 
4.5% 
49 
24.5% 
24.5% 
94 
47% 
47% 
37 
18.5% 
18.5% 
10 
5% 
5% 
1 
0.5% 
0.5% 
200 
100% 
100% 
C-Cyclophosphamide, E-Epirubicin, F- 5-fluorouracil, P-Paclitaxel  
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5.7 Cost of adverse events 
The number of patients experiencing adverse events and the cost of adverse events 
were the highest for patients on palliative therapy. In the sample of 200 patients, 16 
patients presented with adverse events to chemotherapy treatment which led to 
additional health resource utilisation. The number of these occurrences of adverse 
events is displayed in Table 28. Toxicity was scored according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (version 4.0). A toxicity 
grade was assigned to each symptom or adverse effect presented as listed in Table 
28. The most commonly occurring adverse effect within this sample of this study was 
neutropenia while the cases of anaemia, erythema and severe pain were recorded 
once.  
Severe pain, in this case abdominal pain, was documented by Andersen. (2013) as 
one of the common adverse events accompanied by chemotherapy usage. The cases 
of vomiting and diarrhoea were classified in two groups, i.e. grade 2 and 3 with 1 and 
2 patients in each grade respectively. One patient presented with cardiac toxicity and 
the cost was not included in the study as it was not established whether the toxicity 
was due to chemotherapy or to a pre-existing heart condition. 
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Table 28: Occurrences and grade of adverse events  
Adverse effect Grade   Number of patients who had the 
adverse effect  
Neutropenia 3 5 
Thrombocytopenia/ anaemia 3 1 
Cardiotoxicity  4  1, not included in costing model 
Vomiting and diarrhoea 2 
3 
1 
2 
Cellulitis 2 2 
Severe pain  3 1 
Erythema 2 1 
Unknown Ungraded  4 
 
The reason for admission to the hospital was recorded as an adverse effect in the 
patient‟s folder. The cost of treating a patient who presented with vomiting and 
diarrhoea was the highest (R43 904.29) and was followed by neutropenia (R36 
465.82) as shown in Table 29. Some of the patients presented with a combination of 
adverse events (i.e. anaemia, vomiting and severe pain), however the main adverse 
effect was recorded as the reason for admission. For the sample of 200 patients the 
cost of managing adverse events was R210 128. This total cost included the cost of 
hospitalisation, IV antibiotics and antiemetics but did not include the cost of blood 
transfusion and blood products. For the treatment of adverse events the longest length 
of hospital stay was 15 days costing R42 672 for the hospital stay alone.  
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Table 29: Cost of each adverse effect and its component costs (per patient) 
 Hospitalisation 
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(R
) 
Patient 1 Severe 
abdominal 
pains, 
malaise 
8 16002.00 848.79 1642.11 5048.0
0 
 23 540.90 
Patient 2 Neutropenia 8 14224.00 328.76 1302.31  497.00 16 352.07 
Patient 3 Unknown  3 5 334.00 49.79 589.7299  994.00 7 494.52 
Patient 4 Neutropenia 11 33782.00 1042.18 1114.64 527.00  36 465.82 
Patient 5 Vomiting, 
pleural 
effusion, 
shortness of 
breath 
15 42672.00 178.29  1054.0
0 
 43 904.29 
Patient 6 Unknown   86.72   497.00 583.72 
Patient 7 Unknown 4  324.76   1491.00 1 815.76 
Patient 8 Gastritis, 
vomiting 
0.5 889.00 105.38  3051.0
0 
497.00 4 542.38 
Patient 9 Neutropenia 4 7 112.00 1533.77  527.00 497.00 9 669.77 
Patient 10 Neutropenia 5 8 890.00 758.60 181.32   9 829.92 
Patient 11 Vomiting, 
malaise, 
headache 
15 26670.00 581.60 111.87 1054.0
0 
 28 417.47 
Patient 12  
Peripheral 
neuropathy 
3 5 334.00 192.90 134.90  1491.00 7 152.80 
Patient 13 Unknown    57.79   497.00 554.79 
Patient 14 Anaemia 1 1 778.00 65.28 332.50  299.00 8 079.77 
Patient 15 Neutropenia 3 5 334.00 204.20 108.76  497.00 6 143.96 
Patient 16 Erythema, 
cellulitis, 
swelling, leg 
pain 
3 5 334.00 246.40 1 642.11   5 580.40 
 Total 83.5 173355.0
0 
6 605.23 5518.14 
 
11261.
00 
7257.00 210 128.37 
Reason for hospitalisation was recorded for each of the 16 patients presenting with adverse events, the main 
reason for hospitalisation is underlined. 
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The costs of adverse events were categorised based on the patient‟s age and stage at 
diagnosis. Patients who were in stage I cancer and in the youngest age group 18–35 
years did not have any record of adverse events. The rest of the cost distribution is 
explained in Table 30. 
Table 30: Cost of adverse events according to age and stage of cancer at 
diagnosis  
Stage at 
diagnosis 
Cost of adverse 
events per stage 
Average 
cost per 
patient 
Age at 
diagnosis 
 
Cost of adverse 
events per age 
group 
Average 
cost per 
patient 
I R0 (n=0) 
 
R0 18 - 35 R0  (n=0) R0 
II R55 658.94 (n=5) 
 
R11 131.79 36 - 50 R52 977.26 (n=6) R8 829.54 
III R74 402.08 (n=5) 
 
R14 880.42 50 - 65 R118 683.12 (n=8) R14 835.39 
IV R80 067.35 (n=6) 
 
R13 344.56 >65 R38 467.99 (n=2) R19 234.00 
 
Other less severe adverse events beside those recorded in Table 29 were reported in 
the patient medical files. While they were important clinically, their likelihood to 
influence the cost of treatment was negligible as they were managed with routine 
support medication. Examples of these side effects include mild nausea, mild 
vomiting, alopecia, oral thrush (candidiasis) and mild erythema.   
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5.8 Model for predicting the cost of treatment: Decision tree analysis 
This model was developed as an alternative to validate the approach and method 
developed in this study for calculating the cost of treatment. The results of this model 
were based on actual treatment cost at GSH obtained in this study for an episode of 
care period (average 10-12 months). The probabilities of certain events occurring 
(patient completing treatment or not and stages of breast cancer) were calculated and 
summarised in Table 31. The costs obtained from the sample of 200 patients were 
used in the model development. The episode of care cost per patient included all cost 
components studied.  
Table 31: Probability of patient being diagnosed with breast cancer according to 
status of treatment and stage of breast cancer 
 
 
The estimated cost of treating 200 patients with breast cancer was calculated using 
the probabilities of a patient being diagnosed with one of the four stages of breast 
cancer and the chance of a patient completing their chemotherapy treatment.   
Event occurring Probability of event occurring 
 
Patient completing treatment 0.87 
 
 
Stage I  0.08 
Stage II  0.50 
Stage III  0.33 
Stage IV  0.09 
Patient not completing 
treatment 
0.13  
Stage I  0.04 
Stage II  0.40 
Stage III  0.30 
Stage IV  0.26 
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The cost per patient per event was derived from the actual costs obtained from Tables 
19 and 22 for the cost of episode of care. An example is given below for a patient 
diagnosed with stage I breast cancer at GSH: 
200 patients X 0.87 (probability of completing treatment) X 0.08 (probability of being 
stage I breast cancer X R13 646.45 (cost per patient per episode of care, Tables 19 
and 22) = R189 958.58. 
When the costs of the four stages of breast cancer were calculated for 200 patients, 
the sum represented the total cost for the population. The cost for treating breast 
cancer patients with chemotherapy when the patients were able to complete their full 
treatment during their episode of care was R2 566 022.21. Similarly, the cost of 
treatment of breast cancer patients with chemotherapy when the patients were unable 
to complete their treatment during their episode of care was R586 830.65. The total 
estimated cost was R3 152 852.86. It was found that the estimated cost was lower 
than the actual cost by 0.06% (R2 025.04). The result was expected as it estimated 
the cost of breast cancer using the same data set and averages obtained in this study. 
This indicated that the calculated probabilities in the model can be used to predict the 
total cost of treating a full episode of care for breast cancer patients for another data 
set at GSH provided that sample size, stage of breast cancer, treatment status and 
average episode of care cost (Table 19) are known.  
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Table 32: Estimated cost of treating breast cancer patients  
Stage of cancer Predicted total cost for 
complete  treatment  
Predicted total cost for 
incomplete treatment  
Stage I R189 958.58 R14 192.31 
Stage II R1 313 326.77 R156 995.38 
Stage III R968 733.40 R131 593.88 
Stage IV R264 063.46 R113 989.08 
Total for all stages R2 566 022.21 R586 830.65 
Total for all patients 
(n=200) 
  
 R3 152 852.86 
 
Table 32 shows the estimated cost of treating a full episode of care for the patients 
diagnosed with the respective stages of breast cancer at GSH. The cost of treating a 
patient presenting with stage IV disease is the highest whilst stage I cancer is the least 
expensive to treat. The tree diagram (Figure 10) can be used in the calculation of 
these costs. 
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The figures in the green box reflect the probability of occurrence of breast cancer and the probability of completing the treatment or not for the 
various stages of breast cancer. 
Figure 10: Decision tree analysis diagram with costs 
Breast cancer 
patients 
200 
Complete 
treatment 
0.08 
Stage I 
R13 646.45  
R189 958.58 
0.50 Stage II 
R15 095.71 
R1 313 326.77  
0.33 
Stage III 
R16 871.01 
R968 733.40  
0.09 
Stage IV 
R16 862.29 
R264 063.46  
Incomplete 
treatment 
0.04 
Stage I 
R13 646.45  
R14 192.31 
0.40 
Stage II 
R15 095.71 
R156 995.38 
0.30 
Stage III 
R16 871.01 
R131 593.88  
0.26 
Stage IV 
R16 862.29 
R113 989.08 
0.87 
Estimated 
costs 
0.13 
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5.9 Regression model analysis 
 
A regression model was used to analyse dependent and independent variables of cost of 
breast cancer treatment. The multiple regression analysis was used to investigate the 
influence of some specific variables on the cost of treatment. Based on the results of this 
study, the dependent variable was the total cost of treatment, while the independent or 
predictor variables were clinical stage, age at diagnosis, status of treatment 
(complete/incomplete), protocol and treatment approach. For the purpose of the regression 
analysis only, 2 hypotheses were created, 
Ho: There is no relationship between the independent and the dependent variables 
Ha: There is a relationship between the independent and the dependent variables 
The multiple regression equation was computed for the study as; 
TOTAL COST = a + b1(CLINICAL STAGE) + b2(AGE) + b3(STATUS OF TREATMENT) + 
b4(PROTOCOL) + b5(TREATMENT APPROACH) + e 
where, TOTAL COST represents total cost of breast cancer treatment, a is the constant 
term and b1 to b5 represent the slopes of Y of the respective variables. The results of the 
analysis are presented in Table 33.  
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Table 33: Model summary for total cost of treatment of breast cancer 
Model R R Square Adjusted 
R Square 
Std. Error 
of the 
estimate 
Durbin- 
Watson 
F- 
Statistics 
Sig. 
Total cost 0.341 0.117 0.094 1557.046 1.951 5.121 0.001 
R- coefficient of determination, Durbin-Watson – tests for auto correlation in the sample, F- statistics – ratio of the mean 
regression sum of squares divided by the mean error sum of squares, Sig. – statistical significance 
The probability of the F statistic (5.121) for the overall regression relationship is equal to 
0.001, less than the level of significance of 0.05. Hence, the null hypothesis that there is no 
relationship between the cost of treatment and the predictor variables is therefore rejected. 
The alternative hypothesis that there is a statistically significant relationship between a set of 
independent or predictor variables and the dependent variable (cost of treatment) is 
therefore accepted. The coefficient of determination, R squared, which measures the level 
of variation in the dependent variable attributable to the independent variables is 0.117 
(Table 33). The level of variation is therefore translated to 11.7%. This signifies a weak 
relationship between the dependent and independent variables and further implies that only 
11.7% of the total variation in the cost of treatment is explained by the combined influence of 
some or all of the predictor variables. (Refer to section 4.6.1 for other reasons of cost 
variation).  
The model summary confirms that there is a relationship between the total cost of treatment 
of breast cancer and the treatment variables. Hence, those that are statistically significant 
should be taken into account in the development of a method to determine the cost of breast 
cancer treatment. The variables were further tested individually to determine statistical 
significance towards the total cost of treatment of breast cancer. The results are explained in 
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Annexure 7. 
The results of the multiple regression analysis shows there is a statistically significant 
relationship between cost of treatment of breast cancer and status of treatment 
(complete/incomplete) (p<0.001). This is because the probability of the T-statistic for its beta 
coefficients is less than the level of significance of 0.05 of the model. Therefore, it can be 
said that the status of treatment (complete/incomplete) significantly influences the cost of 
treatment. 
Furthermore, statistically insignificant relationships were found between the dependent 
variable and the following individual independent variables; treatment approach, age at 
diagnosis, protocol and clinical stage. This is due to the fact that the T-statistics for their 
respective beta coefficients are greater than the level of significance of 0.05 of the model 
(i.e. sig. of independent variables > 0.05). Although it was expected that these variables 
would show statistical significance, the contrary result could have been due to the small 
sample size used in this study.   
Additional results of the regression model including the scatter plots are attached in 
Annexure 7.  
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CHAPTER 6 
DISCUSSION 
 
According to our knowledge, there is no data currently available on the cost of an episode of 
care for breast cancer in the public sector in South Africa. This study was conducted to 
address this issue.   
The aim of this study was to analyse retrospective data in order to develop a method to 
determine the direct medical cost of management of breast cancer with chemotherapy. In 
developing the method, the costs of chemotherapy per episode of care were determined 
from the funder perspective. All costs associated with chemotherapy were considered.  
Previous studies conducted globally have looked at cancer costing models measuring direct 
medical costs (Davari et al., 2013; Pompen et al., 2009; Maslove et al., 2005), measuring 
direct and indirect medical costs (de Oliveira et al., 2013) and conducting cost effectiveness 
analyses (Korpela et al., 2011). Some of the above studies are similar to our study in 
measuring direct costs only.  
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6.1. Demographics and clinical characteristics 
The study subject characteristics are reported in Table 5. The findings of this study showed 
that 11% of the patients were younger than 35 years of age and the majority (56%) of 
patients were aged between 46 and 60 years; the mean age at the time of diagnosis was 
50. The findings concur with another study conducted in Asia, which estimated the mean 
age at diagnosis of breast cancer to be between 43 and 49 (Davari et al., 2013). A study by 
Hoang Lan et al. (2013), found the mean age of their study subjects to be 51 years and the 
most frequent age group was from 40 to 49 years and comprised 36.4% of patients. These 
show that breast cancer was prevalent in middle age women during the study period. This is 
the general trend of breast cancer in developing countries, which is contrary to the trend 
displayed in the developed countries where breast cancer patients are postmenopausal, i.e. 
60 to 70 years old (Hoang Lan et al., 2013; Anyanwu, 2008). Of the patients in our study, 
approximately one-third presented with locally advanced and one-fifth with metastatic 
disease at the time of diagnosis, similar to what was found by Kaliks et al. (2013), whose 
study was also conducted in a low-middle income country. 
It is reported that on average 10-20 women are diagnosed with breast cancer at GSH every 
week (Western Cape Government online. 2017). In our study, we found that, over a 2 year 
period 1 024 patients were registered in the Radiation Oncology department (ROD) 
following diagnosis of primary breast cancer. Therefore, according to the electronic 
database (MI), it is estimated that 512 patients were diagnosed with breast cancer per year 
at GSH. This is consistent with the report of 2017 on the Western Cape Government 
website which also estimates at least 520 new diagnoses per year. It was found in this study 
that the proportion of those who will go on to be treated with chemotherapy is 68%.  
http://etd.uwc.ac.za
107 
 
6.2. Developed method  
The main focus of this study was to develop a method to determine the costs of breast 
cancer treatment and management of associated adverse events. The developed method 
measured resource use at patient level according to the data that were available from the 
hospital‟s data sources. The method measured costs of chemotherapy and resources linked 
to chemotherapy use, as was partially done by Boutayeb et al. (2010). In their study 
conducted in Morocco, Boutayeb et al. (2010), collected data for cost of treatment of breast 
cancer for early breast cancer. Non-chemotherapy resources, for example, scan and 
imaging procedures, had to be linked to an event involving chemotherapy and had to be in 
the same timeline as the patient‟s episode of care.  
It was established that the methodology for costing breast cancer treatment differs 
according to the nature and the aim of the study. A study by Maslove et al. (2014), utilised a 
similar methodology, as in our study, of quantifying resource use data for treatment of breast 
cancer. The only difference was that their method included the cost of patients admitted to 
hospital for the purpose of chemotherapy administration. In our study, chemotherapy 
administration was conducted as an outpatient ambulatory procedure. The patients who 
were admitted for chemotherapy administration were boarding in a general ward for 
convenience when the chemotherapy administration would be conducted the following day. 
This category of cost was viewed as an indirect cost because the patients were individually 
screened for level of income and radius of their home from the hospital. It was therefore 
argued that cost of an admission under those circumstances could not be included together 
with direct medical cost of management of breast cancer.  
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The cost of hospitalisation in this circumstance was separated from hospitalisation due to 
management of adverse events which was classified under direct medical costs in this 
study.  
It is important to note that the method developed could be applied to other costing projects 
of relevant hospitals. However, the results of this study are an analysis of costs incurred at 
GSH for the particular period of study. The results therefore, cannot be extrapolated to other 
breast cancer treatment centres. However, the methods could be modified for other 
treatment centres.  
It is worth pointing out that the method of patient extraction from the electronic system 
revealed that the EPR was a better platform for breast cancer patient selection compared to 
MI. The system provided a summary of demographic and clinical information for the 
patients, i.e. approach of treatment, treatment plan and histology/ type of breast cancer. A 
database of this nature for breast cancer patients could aid future researchers in collecting 
relevant data without having to consult patient medical folders for this additional clinical 
information. Therefore, it is a recommendation of this study that either an update of this 
database be implemented by the hospital policy makers or the MI database could be 
merged with the EPR database. Merging the databases would provide comprehensive data 
on all breast cancer patients.  
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6.2.1. Time and motion study  
This study showed that the pharmacist time spent during the process of compounding 
chemotherapy was not clearly accounted for by the hospital costing system. A component of 
cost called the „compounding fee‟ was developed in our study and determined by time and 
motion studies. The compounding fee was added to the medicine cost and dispensing fee to 
provide a total cost of chemotherapy medicines. This component that is part of the 
pharmacists‟ scope of practice is noteworthy and therefore it was important that it was 
accounted for (Oglesby et al., 2009). It appears that the UPFS did not account for the 
compounding of chemotherapy separately as it is done in the private sector. 
The National Patient Advocate Foundation, (2005) in their study introduced another 
methodology of a time and motion study motivated by the beta test which determined a 
potential miss of information if time and motion was based only on the top identified drugs 
(Brixner et al., 2005). The survey assessed all tasks conducted by the pharmacist in a 
specified period of time (i.e. in one shift). A list of duties a pharmacist was responsible for on 
a typical day of work was developed and if a task not listed was performed, it was noted 
separately. The methodology improved their quality of results. A broader analysis is crucial 
when resources are sufficient. However, in a time and motion study that focuses on breast 
cancer chemotherapy alone without concomitant drugs (other than support medicines), it 
would be an unnecessary time and resource consuming exercise to measure all tasks 
performed by the pharmacist related to all chemotherapy drugs and support medicines. 
Hence, our study focused on the task of compounding chemotherapy medicines for breast 
cancer only. 
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Even though no studies were found for comparison, the findings of this study will provide the 
funder of care (the government) with an insight of another (apart from the UPFS, scenario 1) 
methodology of calculating costs of components of treating breast cancer at GSH. The 
nurses‟ time taken to administer chemotherapy was reported as an average per patient on 
the cost template. The time and motion study provided the cost for this task which was 
independent from other nurses‟ duties. This provides a reliable assessment of the time 
spent by the nurse on chemotherapy tasks and the cost involved. According to the current 
costing approach based on the UPFS, patients are charged a set fee for the administration 
of chemotherapy.  
The calculation of treatment cost is of particular importance in developing countries where 
the reality of economic constraints can often influence access to appropriate treatment. This 
study agrees with the notion stated by Alleyne-Mike, (2013) which supports a treatment 
option that is economically feasible without undue compromise to patient survival.  
When the method for the time and motion study was compared with a method conducted by 
Haywood et al. (2012), one advantage of our study methodology was that the time 
recordings were conducted by the researcher. The method therefore did not rely on self-
reported information to elicit the amount of time spent on nurses‟ tasks, thus reducing the 
risk of bias and systematic misreporting of time spent. The recording of actual times 
provided an opportunity to measure actual resource use as distinguished from calculating 
costs from the protocol based method as developed by Haywood et al. (2012). A possible 
limitation of our approach was that our method did not reflect the time differences in 
resource use within a particular task. The time difference, however, was considered to be 
small hence the times were recorded for the full task period.  
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One component that is often omitted when conducting time and motion studies for breast 
cancer treatment is the time specialists spend with the patient during chemotherapy 
administration (Haywood et al., 2012). Although small, the direct contact between specialist 
and patient seemed to exist where necessary at GSH. Unless the patient had severe 
adverse events or the nursing sister had a query about the patient, it was assumed that 
there was no reason for the doctor to see the patient during chemotherapy administration 
but rather only at a scheduled consultation after every cycle of chemotherapy. These 
assumptions were factored into the cost calculation by adding an average time (1.32 
minutes) spent by the doctor with the patient. One of the strengths of our study lies in the 
determination of this cost. In the study of Haywood et al. (2012), they failed to quantify this 
cost as their model was not based on actual patient data or time and motion studies.  
6.2.2 Scenario analysis 
The scenarios 1 and 2 developed in this study were explained in full in section 4.12. Many 
studies have agreed that the cost of administration of intravenous chemotherapy and 
resource use has not been studied widely enough (Haywood et al., 2012; Gordon et al., 
2011). Therefore, in our study the cost of treatment was measured using 2 different 
scenarios. There was no reference in literature that studied these scenarios before. The first 
scenario was developed with the standard method of costing utilising the UPFS. For the 
second scenario, where possible, the time and motion studies replaced some UPFS costs. 
When the 2 scenarios developed for the method of costing were compared, it was found that 
there was a negligible difference in costs obtained. The costs of chemotherapy 
administration and doctor consultation based on scenario 2 were found to be less than the 
costs based on scenario 1 by 9%.  
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The cost of compounding chemotherapy increased the total cost of chemotherapy by 5.3%. 
This increase in cost was expected as our assumption was that the compounding fee was 
not taken into account by the UPFS. Hence, our study considered this additional cost. 
The costs of scenario 2, i.e. chemotherapy administration and doctor consultation were 
found to be less than those of scenario 1. Two important differences must be considered 
when comparing results of this study. First, the study did not use the same patient data in 
which the researchers applied costs. The patient data from the retrospective analysis was 
extracted and cost averages obtained from the time and motion studies on prospective 
resource utilisation data were applied to derive the cost of respective components. Second, 
it was discovered that the salary of the nurse used to calculate the cost in scenario 2 may 
not be the best method. The nurses on duty have different levels of qualification and years 
of experience and hence different cost associated with this. Notwithstanding the fact that 
there are other personnel involved, i.e. sister-in-charge over-seeing the practice in the clinic 
and student nurses whose roles could not be accounted for in the costing exercise. The 
impact of a time and motion study was crucial in measuring resource use and actual time 
spent as explained in section 6.2.1. It is worth noting that, although the figures obtained are 
invaluable for analysis, the model can be altered or modified to reflect the local clinical 
practices. For example, changing the type of medical staff involved in the administration of 
chemotherapy from nursing sister to sister-in-charge or from urban nursing sister to rural 
nursing sister (as they might have different salary scales) could be achieved in the same 
model developed in this study.  
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6.3 Cost of breast cancer treatment and adverse events 
For most cost components measured, mean costs were higher than the median costs, which 
suggested that the majority of patients had a lower than average treatment cost, whereas a 
small group generated high costs (Pompen et al., 2009). The minimum costs of treatment 
for some components were as low as R447.48 for laboratory tests and R527 for scans and 
imaging procedures. However, there were some patients who did not receive some services 
at all. These were excluded from the cost template.  
6.3.1 Episode of care cost 
The strength of this cost study lies in the determination of actual costs of treatment at patient 
level for an episode of care. Utilisation data in the routine setting allowed costing of 
chemotherapy in an accurate way without making assumptions of usage (Haywood et al., 
2011). This was crucial in contrast to other studies that make assumptions of cost based 
purely on the protocols being followed (Pettersson et al., 2012).  
The episode of care costs for the patients in this study could not be compared to other cost 
studies conducted internationally. Although the study conducted in Morocco also calculated 
the cost of breast cancer, the treatment protocols were different and the period when the 
study was conducted was different (Boutayeb et al., 2010). Another study conducted in 
Vietnam by Hoang Lan et al. (2013), measured the direct medical costs for a 5-year 
treatment course, thus limiting the chances for comparison of costs due to different 
timeframes. In most cases, the study characteristics were similar, i.e. retrospective patient-
level data, analysis conducted from the health payers‟ perspective and measuring direct 
medical costs per episode of care.  
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However, the costs were derived from the health insurance industry or the costs were not 
direct costs for breast cancer treatment (Hoang Lan et al., 2013, Pagano et al., 2012).  
In some cases, the costs of breast cancer were obtained for chemotherapy, surgery and/or 
radiotherapy (de Oliveira et al., 2013) instead of cost of chemotherapy alone. This further 
compromised the chances for comparison of costs. These studies, helped in shaping the 
methodology of our study and provided a basis for comparison of categorised costs, for 
example, cost based on age and stage of disease.  However, the purpose of this study was 
to develop a method for GSH to determine the cost of breast cancer. It is recommended that 
due to the small sample sizes per subgroup in the analyses these costs should be used with 
caution for budgeting purposes or any other decision making purposes.   
Although not many direct comparisons could be achieved, the total costs of this study were 
found to be generally less as compared to studies conducted in Canada (de Oliveira et al., 
2013) and the USA (Boutayeb et al., 2010). The reason for this could be due to differences 
in population, cancer incidence, socio-economic status and health funding systems. 
However, the study conducted in Vietnam estimated the cost of breast cancer treatment 
over the first 9 months of treatment to be $632.85 (approximately R8 950) and the range 
was $11.70 - $3 955.40  (approximately R165 – R55 935) (Hoang Lan et al., 2013). In our 
study, the episode of care cost was R15 774.39 and the range was R3 480.81 to R38 
627.40. 
All patients evaluated in this analysis received first-line treatment with chemotherapy 
according to the GSH treatment protocols provided.  
http://etd.uwc.ac.za
115 
 
The episode of care period was confirmed to be complete when a patient successfully 
completed the treatment with chemotherapy and a 6 month follow up period was free of 
post-chemotherapy adverse events.  
The reason for the choice of the prescribed chemotherapy was only known by the 
prescribing doctor. However, it could be related to the extent of disease, presence of co-
morbid conditions and likelihood to cause adverse events.  
The data were collected according to the period when each patient was attending the 
hospital. The cost of episode of care in this case is significant in measuring the cost per 
patient (Cipriano et al., 2011).  
6.3.2  Cost drivers and cost of components 
The major cost driver in this study was the category of scans and imaging with cost of 
chemotherapy and dispensing fee following closely thereafter. Procedure and facility per 
patient fees for scans were exceptionally high when compared to other component costs 
(Figure 7). The reason could be attributed to the use of high technology machines which 
required a specialist radiographer and experienced personnel to interpret the results. Some 
studies found that maintenance of these machines is a challenge in developing countries 
(Shah et al., 2015). Although this component is a high cost to the funders of care, it can be 
argued that the role of imaging testing in breast cancer diagnosis and measuring the 
effectiveness of treatment is equally crucial.  
The chemotherapy medicines costs were the second highest among all the cost 
components. The huge variation in cost of chemotherapy within the same patient‟s episode 
of care receiving the same medicines and the same dosage was observed.  
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The variation in chemotherapy prices was mainly accounted for by the variation in the batch 
size compounded on the particular day.  
Following a consultation with a member of the Pharmacy Department at GSH, it was 
discovered that the hospital electronic software was designed to calculate the cost of each 
medicine based on the number of items dispensed of that particular medicine in a day. 
Hence, the more of a specific medicine that was compounded on a particular day, the 
cheaper the medicine was priced. According to the Pharmacy Department at GSH, the JAC 
system calculates a price based on ingredients used in that batch, the price of the ingredient 
and the batch size that was made on the day. 
For example, for an infusion containing 330mg paclitaxel for one patient on a particular day, 
the cost for the dose of 330mg paclitaxel was R989.88. However, if on another day a batch 
of 6 infusions were prepared for different patients, i.e. 1800mg of paclitaxel in total. The total 
cost was spread across all 6 patients resulting in a lower cost of R611.08 per patient. Unlike 
the private sector, linear pricing is not applied. 
6.3.3 Cost of adverse events 
A significant addition to the treatment costs was due to treatment of adverse events, 
especially neutropenic infections. Of these occurrences, adverse events requiring 
hospitalisation accounted for 60% increase in the treatment cost. A study by Lathia et al. 
(2010), reported that the high treatment cost of febrile neutropenia was mainly due to the 
cost of hospitalisation, which is consistent with the results of our study.  
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In our study, the calculated mean cost of R9 669 per hospital stay for an episode of febrile 
neutropenia was found to be very low when compared with £4 688 (approximately R86 900) 
of a Canadian study by Lathia et al. (2010).  
Although the components added by Lathia et al. (2010), were not known, the cost 
differences could be accounted for due to differences in the level of therapy provided by the 
two hospitals, the socio-economic status and the purchasing power parity of the two 
countries. At GSH, the length of stay in hospital was found to be the main cost driver. The 
patients were admitted to the general ward where the cost was charged per 12 hour day. 
The number of events and the subsequent cost of adverse events at GSH may be greater 
than that reported as some events may not have been recorded in the folders. It was also 
found that some patients died before the cause of the adverse events could be established. 
Often the words, “chemotherapy reaction?”, were annotated in the patient folders as the 
doctors were also not aware of the cause of adverse event presented by patient.  
The study by Korpela et al. (2010), analysed cost of toxicity in the treatment of metastatic 
breast cancer and estimated a 20% increase in direct medical costs as measured over a 
period of 6 months treatment. When critically analysed a similar assumption on the increase 
of treatment costs could be made on our data, however taking into consideration the stage 
IV patients only. It is also highly likely that patients who are more prone to severe adverse 
events are late stage patients with metastatic disease. In our study 6 patients in stage IV 
had adverse events while the majority (10) were in other stages of breast cancer.  
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6.3.4 Categorisation of costs 
The findings of this study revealed that the treatment costs were not the same for all breast 
cancer patients. The costs were dependent on a variety of factors i.e. age, stage at 
diagnosis, adverse events and complete or incomplete treatment. Older patients were 
assumed to be costly to treat since there was a greater probability to develop infection or 
presence of other diseases (Astim et al., 2011). It was found in this study that the average 
age at diagnosis was 50 years and almost 50% of patients were older than 50 years. This 
finding coincides with the fact that the risk of developing breast cancer increases with age 
and breast cancer patients are often diagnosed late in life (Davari et al., 2013). The life 
expectancy, however, lowers in the greater than 65 years old group. The prognosis is often 
poor in older patients due to various reasons i.e. presence of comorbidities, late diagnosis 
and risk of developing liver or kidney damage with some chemotherapy medicines. The 46 
to 65 years age group accrued the highest cost of treatment due to the high number of 
patients in this age group (Table 23). Although the age at diagnosis does not seem to have 
a significant impact on the direct medical cost of treatment (p>0.05), there is a chance that 
the indirect cost of treatment could be affected (Davari et al., 2013). However, further study 
is needed.  
It was found in our study that the stage of cancer at diagnosis was probably the most crucial 
parameter in defining the cost of treatment. Several studies in the literature (Hoang Lan et 
al., 2013: Rojnik et al., 2008; Wong et al., 2007; Yilmaz et al., 2007) supported the fact that 
the progress of disease was the main factor influencing the cost of treatment because the 
medical intervention was decided according to extent of spread and stage of disease. 
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Patients with stage I disease had lower costs compared with patients presenting with more 
advanced disease (Gordon et al., 2011).  
The cost of late stage was increased by the likely occurrence of adverse events, treatment 
complications and palliative care (Hoang Lan et al., 2013). In this study, 1 patient in stage IV 
had an episode of care cost of R20 353.07 versus the average cost in that stage group of 
R16 862.29. The patient received 14 cycles of paclitaxel as palliative chemotherapy and 
supportive pain medication.  
In Iran, Davari and colleagues, (2013) reported medication cost to be the main cost 
component for the patients treated in stage III and IV of breast cancer. However, if the cost 
of treatment is measured over a long-term period, i.e. 5 years, it could be argued that the 
cost of treatment is higher in early stages as the chances of survival are higher (Hoang Lan 
et al., 2013). However, the opposite could be true. If diagnosed early there is a greater 
chance of remission and treatment free life in early stages of breast cancer. In our study, the 
cost of treatment was determined for an episode of care period rather than per year or per 5 
years. The cost of treatment was therefore expected to be higher in late stage than in early 
stage breast cancer. At GSH the costs per patient of stage III for breast cancer were found 
to be more than the cost of stage I by 19%. The difference in treatment cost among the 
stages was statistically significant (p-values <0.05). 
The stage of breast cancer at diagnosis served as a defining factor for relative mortality 
rates of the patients and a determinant for breast cancer treatment options. The survival 
rates can be high if the diagnosis is made at earlier stages of breast cancer.  
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However, diagnosis at GSH was often made late as indicated by at least 44% of patients 
diagnosed with late stage cancer. The authors, Astim et al. (2011), recommend the 
allocation of funds for regular mammography screening for all women over the age of 40.  
The results of their study proved that resource use and costs of treatment are minimised 
when breast cancer is diagnosed at an early stage and age (Astim et al., 2011).  
When the patients who were prescribed paclitaxel alone were compared with those who 
were prescribed FEC therapy, the former accrued higher medicine cost. The difference was 
mainly due to the cost of the individual medicines, paclitaxel being more expensive than the 
individual medicines in the FEC protocol. As seen also in a study conducted in Australia, no 
single regimen of breast cancer treatment was consistently more expensive than others 
(Haywood et al., 2012). The FEC protocol was the most frequently prescribed regimen at 
GSH whilst paclitaxel or related regimens were reserved for recurrent disease and extreme 
cases of hypersensitivity to any of the FEC ingredients. 
6.4 Predictive model developed 
Even though no studies were found for comparison, this method allows the funder of care to 
estimate cost of treatment based on actual costs obtained from this study. 
The rationale for a decision tree analysis was for the development of a method to predict the 
costs of treatment using the formula developed.  It was established that the method could be 
used to calculate the estimated total cost of treatment of breast cancer patients at GSH. 
Given that, the factors, i.e. clinical stage of breast cancer, treatment status (whether 
treatment will be completed or not completed) and sample size are known.  
http://etd.uwc.ac.za
121 
 
The decision tree used for determining the total cost of treatment utilise probabilities (Table 
31) and the average costs of treatment obtained in this study (Table 19). The probabilities 
can be used to determine completed or incomplete protocols for the costing of 
chemotherapy. One advantage of this model is that some local factors can be incorporated 
into the model. Information about local resource use and unit costs can be incorporated and 
the model can be altered to reflect local clinical practice when calculating the costs for other 
hospitals and treatment centres. 
The results of our multiple regression analysis singled out 1 (status of treatment) out of 5 
independent variables to be statistically significant to the cost of treatment. The multiple 
regression analysis conducted by Imamura et al. (2017), identified 3 factors (age, cost of 
chemotherapy and cost of support medicines) that significantly contributed to an increase in 
the cost of treatment per cycle. An adjusted R squared value of 0.680 was obtained for their 
study which was conducted over a 5 year period, as compared to 0.117 obtained in our 
study. As part of their methodology, Chang and co-workers (2004), excluded patients with 
extreme outlier of the direct costs of treatment (> $250,000 or $0 per month) from the 
multivariate analysis. When compared with our analysis, where the outliers to the calculated 
costs of treatment were not excluded, it can be argued that the results of our regression 
analysis could have been improved.  
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6.5 Limitations of the study 
The study had the following limitations: 
i. The sample size of 200 patients was not large enough to conduct proper statistical 
analyses. The sample was used in the development of costing methods.  
ii. Several patient folders were missing from the hospital medical records. The 
patients‟ profiles that were incomplete were due to missing folders and these 
patients were replaced by other patients selected by random sampling. 
iii. The cost of the same chemotherapy medicines for the same patient who was 
receiving the same dosage per cycle varied across the data set. The difference in 
costs was due to the hospital batch system that was calculated by the JAC system.  
iv. During time and motion studies more than one nurse was in contact with the 
patient being observed. Since the nurses were all under the supervision of the 
sister-in-charge, it was assumed that the nurse with the highest rank had the 
ultimate responsibility for the patient and hence the cost was determined 
accordingly. 
v. Some patients collected their breast cancer support medicines or had laboratory 
tests conducted from other private hospitals/ pharmacies whilst receiving 
chemotherapy treatment at GSH. These events were not included in the method 
developed and this probably influenced the average cost of treatment per patient.  
vi. The cost of treatment as found by this study methodology might be lower than the 
estimated cost for the hospital. The trends in cost could have been different had 
we included surgery related costs, radiotherapy and same day procedures such as 
lumpectomies.
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
The study provided the costs of breast cancer and the cost of its associated adverse events. 
The costs obtained in this study could assist in the budget allocation and the financial 
decision making process of funders of care such as the government. 
The main value of the present study is its detailed method development and assessment of 
treatment costs incurred during the episode of care period for breast cancer patients treated 
at GSH. 
7.1   Conclusions 
i. The method of costing breast cancer treatment at GSH was successfully developed. 
The total cost of treatment of 200 breast cancer patients managed with 
chemotherapy was R3 154 877.90. The average cost per patient for an episode of 
care was R15 774.39. The average cost for patients who completed treatment was 
1.3 times more than the average cost for patients who could not complete treatment.  
ii. The cost of treating breast cancer for the episode of care based on the variables and 
scenarios taken into consideration ranged from R12 664.76 to R16 259.72 per 
patient. 
iii. The total cost was made up of costs of various components. The cost components 
were chemotherapy medicines, chemotherapy administration, support medicines, 
doctor consultation, laboratory tests, and scans and imaging procedures.  
iv. The main cost drivers on a per patient basis were scans and imaging and 
chemotherapy medication costs.  
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v. The method of costing was developed with 2 scenarios, i.e. scenario 1 (costs derived 
from UPFS) and scenario 2 (costs derived from UPFS and time and motion studies) 
to determine the episode of care cost.  
vi. Out of the 200 patients in this study, 16 patients had a record of adverse events to 
chemotherapy treatment. The total cost of managing adverse events for these 16 
patients was R210 128. The adverse effect with the highest cost of treatment was 
vomiting (R43 904.29). The cost components used in the evaluation of adverse 
events cost were hospitalisation, laboratory tests, support medicines, emergency 
doctor consultation, and scans and imaging procedures. 
vii. The cost of treatment of breast cancer was calculated according to the GSH 
chemotherapy protocol. The average cost per cycle per patient of each regimen on 
the protocol was R615.77, R587.05, R790.14, R718.93 and R874.76 for the FEC, 
EC, FEC-P, EC-P and P regimens, respectively.  
viii. The cost of breast cancer treatment was categorised according to stage, age, 
treatment approach and whether treatment was either primary of salvage. The total 
cost of patients of stage I, II, III and IV breast cancer were R191 050.34, 
R1 479 379.41, R1 096 618.43 and R387 832.70, respectively. The average age at 
diagnosis was 50 years old, while the age group with the most number of patients 
was the 46-65 years category. 
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ix. Time and motion studies were conducted for the following categories, i.e. pharmacist 
compounding fee, administration of chemotherapy and doctor consultation. It took on 
average 9.76, 6.74 and 4.97 minutes of the pharmacist time to compound the FEC, 
EC and P chemotherapy regimens.  
The total cost of medicines was increased by 5.3% when the compounding fee was 
factored into the total cost for chemotherapy. It took on average 16.87 minutes of the 
nurses‟ time to administer chemotherapy to 1 breast cancer patient at GSH. The 
costs of administration of chemotherapy and doctor consultation obtained from the 
time and motion studies were less than the costs recorded on the UPFS. 
x. The predictive model developed in this study was the decision tree model. This model 
was specifically designed for breast cancer patients at GSH. The costs obtained from 
this models apply to GSH only, however, the model could be applied to other public 
hospitals which have an electronic database and accessible patient folders.  
 
7.2  Recommendations 
i. Chemotherapy compounding fee: the hospital billing system may incorporate the 
compounding fee of chemotherapy medicines on all the patients receiving 
chemotherapy via infusion. The cost of pharmacists performing this task is already 
being incurred by the hospital but it is not accounted for.  It was found in this study 
following time and motion studies that the cost of chemotherapy medicines increased 
by 5.3% when the cost of compounding was added. 
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ii. The episode of care cost was calculated per patient and based on whether the 
patient completed or could not complete treatment. These episode of care costs can 
be used for budgeting when funding breast cancer treatment at GSH. 
iii. EPR development: the Electronic patient records are being under utilised at GSH. 
The capacity and capabilities of the MI database could be improved by merging the 
electronic database with the EPR database. In order to fully appreciate its relevance, 
the database needs to be regularly updated the same way the MI is updated. The 
EPR however, is specific for breast cancer patients only. Furthermore, the database 
could be enhanced to include other cancers as well.  
iv. Chemotherapy costs per patient: it was found in this study that the chemotherapy 
costs vary substantially. The variations were noticed for example, for the same 
patient, receiving the same dose of chemotherapy and within the same episode of 
care. The automatic calculation of these costs on the JAC system need to be 
reviewed to improve the pricing of these medicines.  
v. Models developed: the method and models developed in this study can be used by 
GSH in estimating episode of care costs for breast cancer patients being treated with 
chemotherapy. The same methods can be applied at other breast cancer treatment 
centres to estimate the episode of care costs.  
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Annexure 1: GSH Data collection form 
SAMPLE: GSH Breast cancer data collection form   Date………….. 
Patient‟s surname………………………….     Folder number………………………. 
Patient‟s name……………………………  Age…………………………………… 
Date of birth ………….……………………   Gender M/F………………………….. 
Weight (kg) ……………………………….. Height (cm)…………………………..  
BSA…………………………………………      BMI ………………………………….. 
 
INCLUSION CRITERIA                  
18 years and older:    □ YES □ NO                                               
Treatment with chemotherapy:    □ YES □ NO 
Cancer diagnosis: □ Breast 
HISTOPATHOLOGIC TYPE: 
Cancer type Detail 
Breast IDC: □   DCIS: □   LCIS: □    
 Paget‟s disease:  □   Other: □ 
 Detail: 
Date of first consultation (Primary)………………… Date of first consultation 
(relapse)……………… 
Date of first diagnosis (Primary) …………………… Date of first diagnosis (relapse) 
………………… 
Stage of disease: T score………… N score…….. M score………… Clinical stage: 1  2  3  4  
X 
Grade:   □ 1     □2    □ 3    □ X 
PS/ ECOG score:  □ 0   □ 1     □ 2    □ 3    □ 4     
Lymphovascular invasion: □ YES □ NO □ X 
Nuclear grade: □ 1     □ 2    □ 3    □ X     
Metastasis:   □ Yes   □ No   -  If yes:    □ Lung  □ Liver □ Brain □ Bone other ____________  
 If YES: site of initial occurrence____________ 
Receptor status:    □ ER+     □ ER-     □ PR+      □ PR-      □ HER2+     □ HER2-       
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TREATMENT:   
□ Surgery  □ Radiotherapy □ Chemotherapy □ Hormone  □ Other ________________ 
Treatment sequence: ________________ 
□ Adjuvant therapy   □ Neo-adjuvant therapy   □ Palliative  
Date of first treatment for chemotherapy (Primary): ________________ 
Date of first treatment for chemotherapy (Relapse): First __________Second _________ 
Date of first treatment for radiotherapy (Primary): ________________ 
Date of first treatment for radiotherapy (Relapse): ________________ 
Chemotherapy 
medicine 
Prescribed 
Dose /m
2
  
Date of 
administration 
Quantity  
Administered 
per cycle 
Cycle 
number 
Number 
of cycles  
Cycle 
length 
Route   
PO/ IV  
        
        
        
        
        
 
Other supporting 
medicines  
Route  
PO/ IV 
Dose  Frequency  Duration  Date  
      
      
      
      
      
 
Reasons for early termination of chemotherapy treatment 
□  Disease progression □  AE   □ Patient refusal □ Death  □ Other  ___________ 
 
 
 
 
 
 
 
Sequence Key: 
1. Surgery 
2. Chemother
apy 
3. RT 
4. Hormone 
5. Other   
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ADVERSE EVENTS 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______  
Treatment of AE: 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______ 
Rechallenge done  □YES    □ NO             Event reappeared     □ YES     □ NO 
ADVERSE EVENTS OUTCOME 
 Death  
 Life-threatening  
 Disability  
 Hospitalisation  
 Congenital anomaly 
 Other: 
 
LABORATORY TESTS FOR DIAGNOSIS/ STAGING  
TEST DATE COMMENT 
   
   
   
   
   
 
OTHER FOLLOW-UP TESTS FOR MONITORING TREATMENT 
TEST DATE COMMENT 
   
   
   
   
   
 
COMORBIDITIES:  
_________________________________________________________________________
_________________________________________________________________________ 
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Outpatient 
visits 
Date of visit Reason of visit Duration  
1    
2    
3    
4    
5    
 
Hospitalisation  Date of admission Date of discharge Duration Reason for hospitalisation 
1     
2     
3     
4     
5     
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Annexure 2: 
TIME AND MOTION STUDY: pharmacist compounding time for breast cancer chemotherapy 
SAMPLE: DATA COLLECTION FORM       Date……………. 
 
Pharmacist grade: ………………….  Status: Full time/ Part time 
 
KEY: GSH CHEMOTHERAPY COMPOUNDING PROCESS 
Step 1 – Pharmacist interprets the prescription, checks its validity, enters into JAC system, print labels 
Step 2 – Takes folder for oral medicines, selection and assembling of chemo products & consumables from shelf 
into the aseptic unit, cleans work area 
Step 3 – Actual compounding/ mixing of IV chemotherapy, labeling, final check and sign off 
 
Regimen 1: FEC (5-FU, Epirubicin, Cyclophosphamide) 
 Stage 1 
(min) 
Stage 2 
(min) 
Stage 3 (min) Total time 
(min) 
Comments 
F E C 
Patient 1        
Patient 2        
Patient 3        
Patient 4        
Patient 5        
 
Regimen 2: EC (Epirubicin, Cyclophosphamide) 
 Stage 1 
(min) 
Stage 2 
(min) 
Stage 3 (min) Total time 
(min) 
Comments 
E C 
Patient 1       
Patient 2       
Patient 3       
Patient 4        
Patient 5        
 
Regimen 3: Paclitaxel  
 Stage 1 (min) Stage 2 (min) Stage 3 (min) Total time 
(min) 
Comments 
Patient 1      
Patient 2      
Patient 3      
Patient 4      
Patient 5      
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Annexure 3: 
TIME AND MOTION STUDY: Doctor-patient time for breast cancer consultation  
SAMPLE: DATA COLLECTION FORM      Date: 
 
Doctor’s grade: ………………….  Status: Full time/ Part time 
 
Patient RT 
number 
Stage Time patient enters 
Dr‟s office, (min) 
Time patient 
leaves Dr‟s office, 
(min) 
Time spent in 
Dr‟s office, 
(min) 
     
     
     
     
     
     
     
     
 
 
Annexure 4: 
TIME MOTION STUDY: Nurses’ time in administration of chemotherapy  
SAMPLE: DATA COLLECTION FORM      Date: 
 
Nurse’s grade: ………………….  Status: Full time/ Part time 
 Regimen type Time for patient 
education, (min) 
Time for actual 
administration, 
(min) 
Comments 
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Annexure 5: List of fields for data collection 
FIELDS EPR MEDICAL 
INFORMATICS 
FOLDERS 
Patient name & surname x x x 
Hospital number x x x 
Folder number   x 
BSA   x 
Weight   x 
Date of birth x x x 
Date of death x x x 
Gender x x x 
Diagnosis  x x x 
Date of diagnosis   x 
Stage at diagnosis x x x 
Medicine record: type of 
chemotherapy 
 x x 
Dose   x 
Number of cycles   x 
Cycle length   x 
Route of administration  x x 
Date of administration/ 
issue 
 x x 
Cost of chemotherapy    
Name of other medicines 
administered 
 x x 
Dose  x x 
Frequency  x x 
Date of administration/ 
issue 
 x x 
Outpatient visit: Date of 
consultation 
 x x 
Department  x x 
Reason for consultation   x 
Inpatient admission: date 
of admission 
 x x 
Date of discharge   x 
Duration of admission   x 
Reason for hospitalisation   x 
Ward  x x 
Date of lab test  x x 
Lab tests: name of test  x x 
Cost of test  x  
Scans: name of procedure   x 
Date   x 
Cost of procedure    
Adverse events reported   x 
Treatment of adverse 
events 
  x 
 
 
http://etd.uwc.ac.za
145 
 
Annexure 6: Ethics approval certificates 
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University of the Western Cape Ethics Approval  
Prof P Valodia (School of Pharmacy) 
  
Study project: Development of a model to predict the cost of management of cancer with 
chemotherapy at Groote Schuur Hospital 
  
Registration no:                          14/9/48 
  
Ethics:                                         Approved 
- Permission may be needed from GSH Research Ethics Committee 
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Annexure 7: Statistical analyses 
 
 
Statistics tests conducted on the TOTAL cost of breast cancer treatment   
Test  F (Observed 
value) 
 
F (Critical 
value) 
DF1 
 
DF2 
 
p-value 
 
alpha 
Wilk‟s Lambda 6.112 
 
 
1.392 552 
 
64 
 
< 0.0001 
 
0.05 
Pillai‟s Trace  5.155 
 
1.375 552 69 
< 0.0001 
0.05 
Hotelling-
Lawley trace 
7.051 
 
1.457 
 
552 
 
50 
 
< 0.0001 
 
0.05 
Roy‟s greatest 14.440 
 
1.794 
 
184 
 
23 
 
< 0.0001 
 
0.05 
Chi-square 
asymptotic 
approximation 
The test could not be computed as at least one of the determinants of the within-class 
covariance matrices is null 
Fisher‟s Ftest 
Kullback‟s test 
DF- degrees of freedom 
Tests interpretation:  P value less than alpha value means test is statically significant 
 Chi-Square Tests for costs based on clinical stage 
 Value Degree of 
freedom, df 
Asymp. Sig. (2-sided) 
p-value 
Pearson Chi-Square 184.675 6 .000 
Likelihood Ratio 141.440 6 .000 
N of Valid Cases 200   
 
 
   
 
Chi-Square Tests for treatment approach versus stage of breast cancer 
 
 Value Degree of 
freedom, df 
Asymp. Sig. (2-
sided) p-value 
Pearson Chi-Square 14.350
a
 10 .158 
Likelihood Ratio 15.476 10 .116 
Linear-by-Linear 
Association 
.256 1 .613 
N of Valid Cases 200   
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Chi-Square Tests for episode of care costs versus treatment approach 
 Value Degree of 
freedom, df 
Asymp. Sig. (2-
sided) p-value 
Pearson Chi-Square 52.396
a
 20 .000 
Likelihood Ratio 53.631 20 .000 
Linear-by-Linear 
Association 
2.680 1 .102 
N of Valid Cases 200   
 
Regression analysis results 
Model Summary
b
 
Model R R Square Adjusted R 
Square 
Std. Error of the 
Estimate 
Durbin-Watson 
1 .341
a
 .117 .094 1557.0462198 1.951 
a
Predictors: (Constant), Treatment approach, age at diagnosis, complete or incomplete, protocol, clinical stage 
b
Dependent Variable: Total cost Scenario 1 
 
TOTAL COST
a
 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 62072861.388 5 12414572.278 5.121 .000
b
 
Residual 470332228.555 194 2424392.931   
Total 532405089.943 199    
 
a
Dependent Variable: Total cost Scenario 1 
b
Predictors: (Constant), Modality, Age at diagnosis, Com/ incomplete , Protocol, Clinical stage 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za
150 
 
 
Summary of regression coefficients for treatment of breast cancer 
Model Unstandardised 
Coefficients 
Standardised 
Coefficients 
T Sig. 95.0% Confidence 
Interval for B 
Correlation
s 
B Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
Zero-order 
(Constant) 
 
2247.719 748.495  3.003 .003 771.488 3723.951  
Protocol 
 
68.547 112.444 .043 .610 .543 -153.223 290.317 .031 
Com/ 
incomplete 
 
1562.857 326.786 .327 4.783 .000 918.347 2207.367 .314 
Age at diagnosis 
 
-6.936 9.550 -.049 -.726 .469 -25.771 11.899 -.062 
Clinical stage 
 
306.642 189.234 .148 1.620 .107 -66.577 679.862 .063 
Treatment 
approach 
-88.542 235.442 -.035 -.376 .707 -552.896 375.812 .000 
 
 
Regression coefficients
a
 
Model Correlations Collinearity Statistics 
Partial Part Tolerance VIF 
1 (Constant)     
Protocol .044 .041 .913 1.096 
Com/ 
incomplete 
.325 .323 .972 1.029 
Age at 
diagnosis 
-.052 -.049 .985 1.015 
Clinical stage .116 .109 .546 1.831 
Modality -.027 -.025 .522 1.917 
 
a.
 Dependent Variable: Total cost Scenario 1 
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